Non-M non-O HIV strains, fragments and uses

Abstract

The invention provides peptides which are expressed by the env gene of a non-M, non-O HIV-1 virus, in particular a strain designated YBF30. The invention also provides fragments of the peptides that including the V3 loop region and their corresponding nucleotide sequences. The invention further provides kits including diagnostic reagents containing these molecules or immunogenic compositions containing these peptides, as well as methods for screening and typing non-M, non-O HIV-1 viruses and HIV-1 viruses expressing these peptide and/or nucleotide sequences.

Description

The present invention relates to retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, to its fragments and to its uses as a diagnostic reagent and as an immunogenic agent.

The human acquired immunodeficiency viruses HIV-1 and HIV-2 are retrolentiviruses, which are viruses found in a large number of African primates. All these viruses appear to have a common ancestor; however, it is very difficult to prejudge the period at which these different viruses became separated from this precursor. Other viruses which are more distant, but which nevertheless belong to the same group, are found in other mammals (ungulates and felines).

All these viruses are associated with long infections; an absence of symptoms is the rule in monkeys which are infected naturally.

While the origin of HIV-2 appears to be clear on account of its strong homology with the Sooty Mangabey (West Africa) virus, no virus which is closely related to HIV-1 has been found in monkeys. The most closely related viruses are viruses found in two chimpanzees (CPZGAB SIV, ANT SIV).

All the lentiviruses have been found to exhibit substantial genetic variability, and the phylogenetic study of these variants, obtained from a large number of different geographic locations, has enabled 8 subtypes (clades) of HIV-1 to be distinguished, all of which are equidistant from each other. The clades are only a mathematical representation of the expression of the variability: phenetic analysis, which is based on the amino acids rather than on the nucleic acids, gives different results (Korber et al., 1994).

The demonstration of subtypes is in accord with a phylogenetic analysis which does not, to date, have any pathophysiological correlation but, instead, a geographical correspondance. This is because each subtype is mainly found in a particular geographical area. The B subtype is predominant in Europe and the United States whereas two subtypes, i.e. E and B, are found in Thailand and there is a strong correlation between the mode of transmission which, in actual fact, corresponds to a particular population and the subtype found. All the clades have been found in Africa and their distribution across the rest of the world reflects a probability of encounter between persons indulging in high-risk behaviour. The main clade, which is the main one because it is present in substantial proportions in Africa, is clade A. A very great degree of variability has been found in some African countries (G. Myers, 1994; P. M. Sharp et al., 1994). Several subtypes have been characterized in the western central African countries such as the Central African Republic (Murphy et al., 1993) and Cameroon (Nkengasong et al., 1994).

Finally, patients have been characterized who are carriers of viral variants of HIV-1, whose sera have posed detection problems for particular kits which are sold on the French market and whose confirmatory Western blots have been atypical (Loussert-Ajaka et al., 1994; Simon et al., 1994; PCT International Application WO 96/27013).

Analysis of these variants has confirmed the fact that the type 1 HIV viruses should be subdivided into two groups, i.e. the M (major) group and an O (outlier) group, which includes these isolates, as Charneau et al., 1994 had proposed. Analysis of the synonymous mutations/non-synonymous mutations ratio carried out on the sequences of the known O group viruses indicates that this new group is also ancient, even if no more ancient than the M group (Loussert-Ajaka et al., 1995). Its low prevalence to date, i.e. 8% of patients infected with HIV-1 in Cameroon (Zekeng et al., 1994) and 18 cases characterized in France, is thought to be due to factors which are purely epidemiological.

These two groups of HIV-1 form a tree which is in the shape of a double star ( FIGS. 9 to 19 ). Two isolates, i.e. CPZGAB SIV, characterized from a chimpanzee from Gabon (Huet et al., 1990) and CPZANT SIV, characterized from a chimpanzee in the Antwerp Zoo, possess sequences and genetic organizations which are very closely related to HIV-1 but which do not fall within either of these two groups and form two new branches on the phylogenetic tree.

The demonstration of new variants is important for developing sufficiently sensitive and specific reagents for detecting HIV infections, that is to say reagents which do not lead to false-negative or false-positive results, and for developing compositions which are protective in regard to subtypes which do not belong either to the M group or to the O group.

Consequently, the applicant has set itself the objective of providing a non-M, non-O strain, as well as sequences derived from this strain, which are suitable for detecting non-M and non-O HIV-1 variants and which do not lead to false-negative or false-positive results being obtained. In order to do this, the inventors have, in particular, established an algorithm for differentiating between, and confirming, group M and group O HIV-1 infections, thereby enabling them to select non-M, non-O variants.

The present invention relates to a non-M, non-O HIV-1 strain which exhibits the morphological and immunological characteristics of the retrovirus which was deposited on Jul. 2, 1996 under number I-1753 (designated YBF30) in the Collection Nationale de Cultures de Microorganismes (National Collection of Microorganism Cultures), kept by the Pasteur Institute.

A non-M, non-O variant is understood as meaning a type 1 HIV which cannot serologically and molecularly be recognized as belonging to either of these groups.

The present invention also relates to the complete nucleotide sequence of the strain as defined above (SEQ ID No. 1) as well as to nucleic acid fragments which are at least 10 nucleotides in size and which are derived from the said strain.

Fragments of this type which may be mentioned are:

YBF 30 LTR (SEQ ID No. 2),

YBF 30 GAG (SEQ ID No. 3) (gag gene),

YBF 30 POL (SEQ ID No. 5) (pol gene),

YBF 30 VIF (SEQ ID No. 7) (vif gene),

YBF 30 VPR (SEQ ID No. 9) (vpr gene),

YBF 30 VPU (SEQ ID No. 11) (vpu gene),

YBF 30 TAT (SEQ ID No. 13) (tat gene),

YBF 30 REV (SEQ ID No. 15) (rev gene),

YBF 30 ENV gp160 (SEQ ID No. 17) (env gene),

YBF 30 NEF (SEQ ID No. 19) (nef gene),

the SEQ ID Nos. 21-57, also designated, respectively, YLG, LPBS.1, GAG Y AS1.1, GAG Y AS1, GAG 6, GAG Y S1, GAG Y S1.1, GAG Y S1.2, YRT AS1.3, YRT AS1.2, YRT AS1.1, YRT 2, YRT AS1, YRT 2.1, YRT 2.2, YRT 2.3, YRT 2.4, 4481-1, 4481-2, 4235.1, 4235.2, 4235.3, 4235.4, SK69.6, SK69.5, SK69.4, SK69.3, SK69.2, SK69.1, SK68.1, SK68.2, SK68.3, LSI AS1.3, LSI AS1.2, LSI AS1.1, LSI A1, YLPA, as well as any sequence which is not identical to one of the above nucleotide sequences or is not complementary to one of these sequences but is nevertheless capable of hybridizing specifically with a nucleic acid sequence derived from a non-M, non-O HIV-1 virus.

Such sequences can be used in the specific identification of a non-M, non-O HIV-1, and as diagnostic reagents, either alone or pooled with other reagents, for the differential identification of any HIV-1.

These sequences may, in particular, be employed in diagnostic tests which comprise either a direct hybridization with the viral sequence to be detected or an amplification of the said viral sequence, with these tests using, as primers or as probes, an oligonucleotide which comprises at least 10 nucleotides and which is included in any one of the above sequences, in particular one of the abovementioned sequences, SEQ ID Nos. 21-57.

The present invention also relates to HIV-1 viruses which are characterized in that they differ both from the M group and from the O group and exhibit the following characteristics:

little or no serological reactivity with regard to proteins of the M and O groups and strong serological reactivity with regard to proteins which are derived from the YBF30 strain or the CPZGAB SIV strain;

absence of genomic amplification when using primers from the env and gag regions of HIV-1 viruses of the M and O groups;

genomic amplification in the presence of primers which are derived from the YBF30 strain, as defined above; and

homology of the products of the envelope gene which is >70% with regard to the YBF30 strain.

The invention also relates to the use of the above described sequences for implementing a method of hybridization and/or of gene amplification of nucleic acid sequences of the HIV-1 type, with these methods being applicable to the in-vitro diagnosis of the potential infection of an individual with a virus of the non-M, non-O HIV-1 type.

This in-vitro diagnostic method is carried out using a biological sample (serum or circulating lymphocyte) and comprises:

a step of extracting the nucleic acid which is to be detected and which belongs to the genome of the virus, which virus may possibly be present in the biological sample, and, where appropriate, a step of treating the nucleic acid using a reverse transcriptase, if this nucleic acid is in RNA form,

at least one cycle comprising the steps of denaturing the nucleic acid, of hybridizing with at least one sequence in accordance with the invention and, where appropriate, extending the hybrid, which has been formed, in the presence of suitable reagents (polymerizing agent, such as DNA polymerase and dNTP), and

a step of detecting the possible presence of the nucleic acid belonging to the genome of a virus of the non-M, non-O HIV-1 group type.

The following conditions are employed for the PCR using the primers derived from the YBF30 strain:

extracting the lymphocytic DNA by means of the phenol/chloroform technique and quantifying it by spectrophotometry at a wavelength of 260 nm. All the amplifications are carried out using a Perkin Elmer 2400 thermocycler.

the long (9 kb) PCRs are carried out using an XL PCR kit (Perkin Elmer) in accordance with the manufacturer's conditions and using the dNTP's, the buffers provided and Perkin Elmer's “hot start”; the amplification cycles of this long PCR are:

1 cycle of denaturation for 2 minutes at 94° C.,

then 16 cycles: 15 seconds at 94° C., 15 seconds at 55° C., 8 minutes at 68° C.,

then 24 cycles: 15 seconds at 94° C., 15 seconds at 55° C., 8 minutes at 68° C., adding a further 15 seconds (incrementation) to each cycle.

the nested PCRs are carried out on the amplification products of the long PCRs. The conditions for carrying out the nested PCRs are as follows:

“Expand High Fidelity PCR System” Taq polymerase buffer and enzyme from Boehringer Mannheim in accordance with the manufacturer's instructions, dNTP and “hot start” from Perkin Elmer,

200 μmol of each dNTP, 20 pmol of each primer in accordance with the invention, 5 μl of DNA, 10 μl of 10×PCR buffer and 2.6 units of Taq polymerase in a volume of 100 μl,

amplification: one cycle of 2 minutes at 94° C. followed by 38 cycles: 15 seconds at 94° C., 15 seconds at 55° C., a time of elongation at 72° C. which varies in accordance with the size of the PCR product to be amplified (from 30 seconds to 2 minutes) and a final elongation cycle of 10 minutes at 72° C.

The amplified product is preferably detected by direct sequencing.

The invention also relates to a peptide or a peptide fragment which is characterized in that it can be expressed by a non-M, non-O HIV-1 strain or using a nucleotide sequence as defined above, and in that it is capable: (1) of being recognized by antibodies which are induced by a non-M, non-O HIV-1 virus, as defined above, in particular the YBF30 strain or a variant of this strain, and which are present in a biological sample which is obtained following an infection with a non-M, non-O HIV-1 strain, and/or (2) of inducing the production of anti-non-M, non-O HIV-1 antibodies.

Peptides of this type which may be mentioned are, in particular, those which are derived from the YBF30 strain, in particular: that which is expressed by the gag gene (SEQ ID No. 4), that which is expressed by the pol gene (SEQ ID No. 6), that which is expressed by the vif gene (SEQ ID No. 8), that which is expressed by the vpr gene (SEQ ID No. 10), that which is expressed by the vpu gene (SEQ ID No. 12), that which is expressed by the tat gene (SEQ ID No. 14), that which is expressed by the rev gene (SEQ ID No. 16), that which is expressed by the env gene (SEQ ID No. 18), or one of its fragments such as a fragment of the V3 loop region, i.e. CTRPGNNTGGQVQIGPAMTFYNIEKIVGDIRQAYC (SEQ ID No. 58), and that which is expressed by the nef gene (SEQ ID No. 20), or a fragment of these peptides which are capable of recognizing the antibodies which are produced during an infection with a non-M, non-O HIV-1 as defined above.

The invention also relates to immunogenic compositions which comprise one or more translation products of the nucleotide sequences according to the invention and/or one of the peptides as defined above, obtained, in particular, by synthetic means.

The invention also relates to the antibodies which are directed against one or more of the above-described peptides and to their use for implementing methods for the in-vitro, in particular differential, diagnosis of the infection of an individual with a virus of the HIV-1 type using methods which are known to the skilled person.

The present invention encompasses all the peptides which are capable of being recognized by antibodies which are isolated from an infectious serum which is obtained after an infection with a non-M, non-O HIV-1 strain, and the peptides which are capable of being recognized by an antibody according to the invention.

The invention furthermore relates to a method for the in-vitro diagnosis of a non-M, non-O HIV-1 virus, which method is characterized in that it comprises bringing a biological sample, which has been taken from a patient, into contact with antibodies according to Claim 10, which may possibly be combined with anti-CPZGAB SIV antibodies, and detecting the immunological complexes which are formed between the HIV-1 antigens, which may possibly be present in the biological sample, and the said antibodies.

The invention also relates to a kit for diagnosing HIV-1, which kit is characterized in that it includes at least one reagent according to the invention.

Apart from the provisions which have been described above, the invention also comprises other provisions which will be evident from the description which follows and which refers to examples of implementing the method which is the subject of the present invention and also to the attached drawings, in which:

FIGS. 1 to 7 illustrate the location of the different primers on the genome of the YBF30 strain;

FIG. 8 illustrates the genomic organization of the YBF30 strain;

FIGS. 9 to 16 depict the phylogenetic analysis of the different genes of the YBF30 strain as compared with group M HIV-1 and group O HIV-1 (FIG. 9 : ltr gene, FIG. 10 : gag gene, FIG. 11 : tat gene, FIG. 12 : rev gene, FIG. 13 : vif gene, FIG. 14 : env gp120 gene, FIG. 15 : env gp41 gene, FIG. 16 : nef gene, FIG. 17 : pol gene, FIG. 18 : vpr gene, FIG. 19 : vpu gene);

FIG. 20 illustrates the percentage genetic distance between YBF30 and HIV-1/CPZGAB SIV.

It should of course be understood, however, that these examples are given solely by way of illustrating the subject-matter of the invention, of which they in no way constitute a limitation.

EXAMPLE

Obtaining a Non-M, Non-O HIV-1 Variant According to the Invention (YBF30) and Its Uses

This was, in particular, possible in connection with studying the epidemiology of infection with human acquired immunodeficiency viruses (HIV) in Cameroon, which epidemiology is especially paradoxical. In this country, the diversity of the strains is remarkable as most of the subtypes of the M (major) group of HIV-1 viruses known to date have been reported. Cases of infection with highly divergent HIV-1 viruses of the O group (O for outlier) have been reported, almost exclusively in patients of Cameroonian origin. Cases of infection with HIV-2, HTLV-1 and HTLV-2 subtypes A and B have also been reported.

Taking as a basis the results of previous serological and genotypic assessments, the inventors established an algorithm for differentiating between and confirming infections with HIV-1 viruses of the M and O groups in order to select non-M, non-O variants.

These methods were applied to samples which were sent to the National Reference Laboratory for HIV infections at Yaoundé and made it possible to characterize a highly divergent HIV isolate and to define the tools for characterizing a new HIV-1 group, taking into account the homologies which were observed between this human strain YBF30 and the simian strain CPZGAB SIV.

I—Way of Serologically Characterizing the YBF30 Variant during the Epidemiological Study

1) Collecting the Samples

All the adult patient sera which were sent to the Yaoundé reference laboratory in 1994 and 1995 for detecting or confirming an HIV infection were studied (n=8831).

2) Differentiating Serologically between Group M and Group O HIV-1, and Selecting Variants

If there was positive detection of anti-HIV antibodies (Génélavia Mixt indirect mixed HIV-1 and HIV-2 EIA, Sanofi-Pasteur, Paris, France), this was then combined with an EIA test based on the principle of competition with a specific antigen of the M group (Wellcozyme Rec HIV-1, Murex, Dartford, UK).

If the competitive Wellcozyme Rec HIV-1 test is positive, with a ratio for the reactivity in optical density (OD) as compared with the threshold or cut-off (CO) value which is greater than 5 (CO/OD >5), the serum is regarded as being HIV-1-positive, a result which should be confirmed on a new sample.

The choice of a reactivity ratio which is greater than 5 for regarding the competitive test as being a test for confirming infection with HIV-1 is based on experience acquired by the virology laboratory of Bichat hospital: all of 7200 samples which reacted with a ratio >5 gave a strongly positive HIV-1 Western blot (WB, New Lav Blot 1, SDP, Marnes la Coquette). Apart from cases of HIV-1 seroconversion, the samples which are confirmed as being HIV-positive and which give a Wellcozyme ratio of <5 correspond either to infections with HIV-2 or to infections with C group HIV-1 or other HIV-1 variants.

In order to eliminate the false-positive reactions when carrying out a mixed EIA detection, the samples which give a CO/OD ratio of <5 are tested systematically with a third generation mixed HIV-1/HIV-2 EIA (Enzygnost Plus, Marburg, Germany) which includes antigens of the M and O HIV-1 groups (recombinant gp41 of the MVP5180 strain). If this test is positive, a rapid test which discriminates between HIV-1 and HIV-2 (Multispot, SDP, Marnes la Coquette) and a Western blot (WB, New Lav Blot 1 or 2, SDP) are then carried out.

3) Serologically Confirming Infections with O Group HIV-1 and HIV-1 Variants

All the samples which give a CO/OD ratio of <5, and which have been differentiated as being positive by WB (positivity criteria: 2 ENV+/−POL+/−GAG or 1 ENV+POL+/−GAG) and HIV-1, are tested with a dot blot test using peptide antigens of the V3 and transmembrane regions (InnoLia, Innogenetics, Ghent, Belgium).

4) Retroviral Isolation of the Group O and Variant Strains

The peripheral blood mononuclear cells (PBMC) from the seropositive patients were isolated by Ficoll-Hypaque gradient in Cameroon and then stored, and transported to Paris, in liquid nitrogen.

After thawing, the PBMCs from the patients were cocultured together with lymphocytes from seronegative Caucasian donors. Viral replication in the culture supernatants was demonstrated by detecting reverse transcriptase activity and by carrying out tests for detecting the p24 antigen (Elavia p24 polyclonal, SDP) over a period of one month.

5) Sequences

The PCR products are visualized on agarose gels of from 1 to 1.4% concentration, depending on the size of the fragments, precipitated in 3M sodium acetate (1:10) and 3 volumes of absolute ethanol, incubated at −80° C. for 30 minutes and then centrifuged at 13,000 rpm for 20 minutes. The pellet is dried and then taken up in 10 μl of distilled water (Sigma). Purification is carried out on a “Qiaquick Gel Extraction kit” (Qiagen) in accordance with the manufacturer's instructions; the products are sequenced on an automated DNA sequencer (Applied Biosystems, Inc., Foster City, Calif.) using an Applied Biosystem Dye Terminator kit, as previously described (Loussert-Ajaka et al., 1995); the nucleotide sequences are analysed on Sequence Navigator software (Applied Biosystems), and aligned using GeneWorks software (Intelligenetics Inc.).

6) Phylogenetic Analyses

The sequences were aligned using the CLUSTAL software for multiple alignments and taking, as the reference matrix, the alignments of the compilation of HIV sequences possessed by the Laboratory of Biology and Theoretical Biophysics, Los Alamos, N. Mex., 87545 USA.

The phylogenetic analyses were performed using the PHYLIP software; the distances were firstly calculated using DNADIST, after which the phylogenetic analysis was carried out using NEIGBOR JOINING or FITCH; finally, the trees were drawn using DRAWTREE ( FIGS. 9 to 19 ). The genetic distance percentages are also shown in FIG. 20 .

SEQBOOT was first of all used for the “bootstrapping” analyses, followed by DNADIST and NEIGHBOR JOINING or FITCH. Finally, the bootstrap values were obtained using CONSENS.

II—Results of the Investigation for Detecting Group O and Variant HIV Viruses

174 samples, out of 3193 samples found to be positive in the screening, were regarded as being group O or group M with abnormal serological reactivity or as being variants.

III—Detection of a Non-group O and Non-group M Sample Exhibiting Abnormal Serological Reactivity

The 174 sera which were HIV-1-positive by WB (Western blot), but reactive with a CO/OD ratio of <5 in the competitive EIA, were tested by differential LIA dot blot on the V3 peptides from group M, group O and CPZGAB SIV:

7 do not react with any of the peptides represented (M, O or CPZGAB SIV). The absence of any cell collection does not allow any conclusion to be drawn.

82 give a reactivity with regard to at least one of the peptides corresponding to the V3 loop of O group strains. The frequency of the crossreactions is low and restricted to the epitopes which correspond to the consensus V3 regions (11%) and to the CPZGAB SIV V3 regions (43%).

84 sera do not react with the O group epitopes. Most of these samples were obtained from patients exhibiting an AIDS syndrome (75/84).

one serum, which was taken from a Cameroonian patient (NJ) reacts exclusively with the CPZGAB SIV peptide. This isolated reactivity with regard to a CPZGAB SIV antigen has never been described previously. Since lymphocytes had been collected from the patient, it was possible to continue with the virological characterization of this strain, which was termed YBF30.

IV—Results of the Serological and Virological Examinations Performed on the First Samples Taken from this Patient (May 1995) (Serum No.: 95-6295)

1) Commercial ELISA Tests (Optical Density/Threshold Value)

Criterion of positivity: OD/CO >1

Génélavia=>15

Wellcozyme CO/OD=1.55

Abbott Plus=>15

Behring Plus=4.2

2 ) Western Blot

New Lav 1 Pasteur WB:

160++, 120++, 68++, 55+, 41+, 40+/−, 34++, 24++, 18+

3) Innogenetics LIA Dot Blot

Negative for all the group O and group M bands apart from CPZGAB SIV V3

4) Results of the Investigative Serological Examinations Carried Out on Peptides which are Specific for the M and O Groups

The technique developed by Professor Francis Barin of the Virology Laboratory of the Tours CHU was modified (Barin F. et al., 1996); use was made of synthesized transmembrane region peptides (BioMérieux) for developing a test for differentiating between the M and O groups. This technique is based on antibody-binding competition between the transmembrane gp41 peptides of the O and M groups, which are deposited on the solid phase, and gp41 transmembrane peptides either of the O group or of the M group at higher concentration in a hyperosmolar liquid reaction phase. The results are shown in Table I below, in which the CP well corresponds to the 100% inhibition control and the CSP well corresponds to the 0% inhibition control.

TABLE I
Results of the inter-group O-group M differentiations
for the 6295 serum
	gp41 M	gp41 O	CP	CSP
6295	0.25	0.36	0.12	1.98

These results demonstrate that there is strong binding with regard to the peptides of the solid phase (CSP) and a marked inhibition due to the combined addition of the M and O peptides (CP), but no clear differentiation either by the M peptide or by the O peptide. This is, therefore, serological evidence that the infecting strain does not belong either to the M group or to the O group.

In view of an isolated reactivity in the InnoLia dot blot with regard to the CPZGAB SIV V3 antigens, on the same bases of competition between peptides, this serum was studied by bringing into competition the gp41 M, gp41 O and gp41 CPZGAB SIV peptides.

Use of the serum from the chimpanzee named ‘Amandine’ (donated by M. Peeters, who isolated the CPZGAB SIV strain, AIDS 1992) initially enabled this technique to be validated. In Table II, the lowest values (OD) indicate the highest degree of binding to the antigens.

TABLE II
Results of the inter-group O-group M-CPZGAB SIV
differentiations using the Amandine chimpanzee serum
and the 6295 serum
			gp41
	gp41 M	gp41 O	CPZGAB	CP	CSP
	Amandine	0.8	1.4	0.3	0.5	1.9
	6295	0.7	1.1	0.7	0.4	2.1

The reactivity of the “Amandine” serum confirms and validates the test according to the invention and shows that, while the serum of the patient reacts identically with regard to the M and CPZGAB SIV peptides, it does not exhibit a crossreaction with the O peptide.

These results demonstrate that the group M gp41 and CPZGAB SIV gp41 peptides exert a similar inhibition on the serum of the patient. The antigens of the infecting strain have therefore given rise to antibodies which recognize the group M and CPZGAB SIV gp41 peptides in a similar manner.

4) Results Obtained from the Lymphocyte Isolation (Sampling of May 1995)

A retrovirus was isolated, using standard techniques, from the lymphocytes which were sampled on May 22, 1995. Culture using the MT2 cell line shows that the YBF30 strain does not form any syncytia (NSI).

V—Results of the Serological Examinations Carried Out on the Second Blood Sample (November 1995) (Serum No. 95-3371)

1) Innogenetics LIA Dot Blot

Negative for all the bands, apart from CPZGAB SIV V3

2) Results of the Investigative Serological Examinations Carried Out on the Peptides Specific for the M and O Groups

Table III shows the results of the inter-group O-group M-CPZGAB SIV gp41 differentiations using the 3371 serum.

TABLE III
Results of the inter-group O-group M-CPZGAB SIV gp41
differentiations using the 3371 serum
	gp41 M	gp41 O	gp41 CPZGAB	CP	CSP
3371	1.31	1.7	0.89	0.54	2.02

These results confirm, on this new blood sample (taken from the same patient in the terminal stage of the disease), that the CPZGAB SIV gp41 peptide markedly inhibits the serum of the patient.

The antigens of the infecting strain have therefore induced antibodies which preferentially recognize the CPZGAB SIV gp41 peptide.

3) Results from the Lymphocyte Isolation (Blood Sampling of November 1995 (95-3371-YBF31))

A retrovirus was isolated, using the standard techniques, from the lymphocytes which were sampled in November 1995 and termed YBF31; the sequence elements are identical to those of YBF30.

VI—Genomic Amplification and Sequences of YBF30

The DNA for all the PCR manipulations is extracted from the cells obtained at the end of a positive culture.

The PCRs carried out using the O group HIV-1 primers are negative in the different regions tested (gag, pol, env). Similarly, those carried out using the primers which are specific for M group HIV-1 are also negative.

The amplification and hybridization conditions for the O group PCRs are those described in Loussert-Ajaka, 1995. The amplification and hybridization conditions for the M group PCRs are those described by the authors cited below.

These M group primers are located in accordance with the HIV-1 HXB2 sequence as follows:

in env gp120: ED3/ED12 (position 5956-5985; 7822-7792); ED5/ED14 (6556-6581; 7960-7931); ED5/ED12; ED3/ED14; ES7/ES8 (7001-7020; 7667-7647) (Delwart et al. Science 1993; 262: 1257-1261).

in env gp41: first PCR, ED3/M29, followed by a nested PCR, M28/M29 (7785-7808; 8099-8124); M28/M29 have the following sequences:

M28: CGGTTCTT(AG)GGAGCAGC(ACT)GGAAGCA,

M29: T(CT)T(ACGT)TCCCA(CT)T(AT)(CT)A(AGT)CCA(AGT)GTCAT; SK68/SK69 (Ou et al. Science, 1988; 239: 295-297).

in gag: Amplicor Roche Diagnostics systems; nested gag primers (Loussert-Ajaka et al. Lancet 1995; 346: 912-913); SK38/SK39 (Ou et al., Science, 1988; 239: 295-297).

in pol: A/NE1 (Boucher et al., Lancet, 1990; 336: 585-590); Pol3/Pol4 (Lauré et al., Lancet, 1988, ii, 538-541).

Only the PCRs carried out using the H Pol primers (4235/4538) are positive, with this being followed by a nested PCR using the primers 4327/4481 (Fransen et al., Molecular and Cellular Probes 1994; 8: 317-322). This H Pol fragment, which is located in the integrase (260 bp), has been sequenced. Amplification using the HPOL primers is made possible due to the excess of virus. This is because the DNA which is used is extracted from cells at the end of a strongly positive culture (reverse transcriptase >100,000 cpm). It is not possible to amplify the DNA which is extracted from fresh cells without coculture because of the large number of mispairings between the HPOL primers (especially in the 3′ region) and the sequence of the YBF30 isolate. Conservation of this 3′ end is very important for the extension activity of the Taq polymerase.

1—Sequence of the pol gene: the use of very degenerate primers for amplifying, by RT-PCR, the RNA extracted from the positive culture supernatant gave a positive amplification. These are primers which are common to all retroviruses (Donehower et al. J. Virol. Methods 1990; 28: 33-46), and are located in the reverse transcriptase region of the pol gene. Analysis of the fragment after sequencing made it possible to generate a specific primer, i.e. YRT2 (SEQ ID No.32), from the YBF30 isolate and to amplify the pol gene using the Hpol 4481 primer (Fransen et al., 1994, loc. cit.) as the antisense primer. The fragment was sequenced by synthesizing specific primers as required for each fragment generated (FIG. 1 ).

2—Sequence of the env gene: the second approach was to perform a long PCR (XL-PCR, Perkin Elmer), thereby amplifying all the virus (9000 bp) using primers situated in the LTR: LPBS 1 (SEQ ID No.22); LSiGi, followed by a 6000 bp nested PCR using YRT2 (SEQ ID No.32)/SK69, and to sequence all the envelope following the same procedure. The gp41 region was sequenced using a nested PCR and employing the primers SK68/LSiGi.

3—Sequence of the gag gene: use of a nested PCR, achieved by means of a long PCR (LPBS 1/LSiGi), employing the primers Gag 5 and Gag 11i, and generating from this specific primers, as required, in order to walk along the viral genome.

VII—Results of the Sequencings

The strain YBF30 was sequenced completely (see list of sequences). The YBF31 strain of November 1995 was sequenced in part, and the absence of significant variation confirms the validity of the YBF30 sequences.

VIII—Synthesizing Peptides of the V3 Loop Region of the YBF30 Strain

Studying the sequences of the V3 loop region made it possible to synthesize the corresponding peptide and to compare the amino acids of this region of the YBF30 strain with those of other M subtypes and O strains.

The sequences of the peptides are:

YBF30: SEQ ID No.58

CPZGAB SIV: CHRPGNNTRGEVQIGPGMTFYNIENVYGDTRSAYC (SEQ ID No.59)

GROUP O: CIRPGNRTYRNLQIGPGMTFYNVEIATGDIRKAFC (ANT70) (SEQ ID No.60)

GROUP M: CTRPNNNTRKSVRIGPGQAFYATGDIIGDIRQAHC (SS-TYPE A) (SEQ ID No.61)

The peptide was synthesized, starting with the two asparagines of the 5′ region of the loop, and used in accordance with the same principle as previously described (see IV 4)), namely in competition in relation to the peptides of the M group, the O group and CPZGAB SIV. The results shown in Table IV confirm the original nature of this strain and the possible spread of these strains, since the serological results favour infection of the YBF30 type in Cameroon. Furthermore, a study of 200 selected HIV-1-positive sera from Cameroon provides evidence of a new case exhibiting a profile which is similar to that of YBF30.

TABLE IV
Study of the reactivity of 200 sera
Serum	Origin	V3A	V3cpz	V3YBF30	CP	CSP
953371	Cameroon	1.66	0.38	1.39	0.39	1.64
956295	Cameroon	1.72	0.37	1.16	0.51	1.73
967321	Cameroon	0.07	0.17	0.5	0.05	0.27
Amandine	GABSIV	1.74	0.14	1.48	0.19	1.74
NOA. *	ANTSIV	2.66	0.31	1.88	0.46	1.9
* serum from CPZ ANT SIV

The reactivity of the sera 953371 and 956295, corresponding to the patient from whom the YBF30 strain was isolated, with the CPZ SIV peptide, was confirmed in this new test. The lower reactivity with regard to its own V3 antigen is usual during the late stages of the disease. Nevertheless, this reactivity remains greater than that raised with regard to the M peptide. Another Cameroonian patient (serum 967321) exhibits the same profile of peptide reactivity.

REFERENCES

Barin F. et al., Aids Research and Human Retroviruses, 1996, 12, 13, 1279-1289, Diversity of Antibody Binding to V 3 Peptides Representing Consensus Sequences of HIV Type 1 Genotypes A to E: An Approach for HIV Type 1 Serological Subtyping.

Charneau P., Borman A M., Quillent C., Guétard D., Chamaret S., Cohen J., Rémy G., Montagnier L., and F. Clavel, Virology, 1994, 205, 247-253, Isolation and envelope sequence of a highly divergent HIV -1 isolate: definition of a new HIV -1 group.

Descamps D., Collin G., Loussert-Ajaka I., Saragosti S., Simon F. and F. Brun-Vezinet. AIDS, 1995, 9, 977-978, HIV -1 group O sensitivity to antiretroviral drugs.

Huet, T., Cheynier R., Meyerhans A., Roelants G., and S. Wain-Hobson, Nature, 1990, 345, 356-359, Genetic organization of a chimpanzee lentivirus related to HIV -1.

Korber B T M., MacInnes K., Smith R. and G. Myers, J. Virol., 1994, 68, 6730-6744, Mutational trends in V 3 loop protein sequences observed in different genetic lineages of HIV -1.

Loussert-Ajaka I.,Ly T D., Chaix M L, Ingrand D., Saragosti S., Couroucé A M., Brun-Vezinet F. and F. Simon, Lancet, 1994, 343, 1393-1394, HIV -1/ HIV -2 seronegativity in HIV -1 subtype O infected patients.

Loussert-Ajaka I., Chaix M L., Korber B., Letourneur F., Gomas E., Allen E., Ly T D., Brun-Vezinet F., Simon F. and S. Saragosti, J. Virol., 1995, 69, 5640-5649, Variability of HIV type 1 group O strains isolated from Cameroonian patients living in FRANCE.

Murphy, E., B. Korber, Georges-Courbot, M C., You B., Pinter A., Cook D., Kienky M P., Georges A., Mathiot C., Barré-Sinoussi F., and M. Girard, AIDS Res. Hum. Retroviruses, 1993, 9, 997-1006, Diversity of V 3 region sequences of human immunodeficiency viruses type 1 from the Central African Republic.

G. Myers, Aids Res. Hum. Retrovir., 1994, 10, 11, 1317-1324, Tenth Anniversary Perspectives on AIDS.

Nkengasong, J. N., Janssens W., Heyndrickx L., Fransen K., Ndumbe P M., Motte J., Leonaers A., Ngolle M., Ayuk J., Piot P., and G. Van der Groen, AIDS, 1994, 8, 1405-1412, Genotypic subtypes of HIV -1 in Cameroon.

Sharp P. M. et al., AIDS, 1994, 8, suppl. 1, S27-S42, Origins and diversity of human immunodeficiency viruses.

Simon, F., T. D. Ly, A. Baillou-Beaufils, V. Schneider-Fauveau, J. de Saint-Martin, I. Loussert-Ajaka, M. L. Chaix, S. Saragosti, A. M. Couroucé, D. Ingrand, C. Janot, and F. Brun-Vezinet. AIDS, 1994, 8, 1628-1629. Sensitivity of screening kits for anti - HIV -1 subtype O antibodies.

Zekeng, L., L. Gurtler, E. Afane Ze, A. Sam-Abbenyi, G. Mbouni, Essomba, E. Mpoudi-Ngolle, M. Monny-Lobbe, J. B. Tapko, and L. Kaptue, AIDS, 1994, 8, 1626-1628, Prevalence of HIV -1 subtype O infection in Cameroon: preliminary results.

As is evident from the above, the invention is in no way limited to those of its embodiments which have just been described more explicitly; on the contrary, it encompasses all the variants which may come to the mind of the skilled person without departing from the context or scope of the present invention.

98 1 9183 DNA Human immunodeficiency virus type 1 1cttctcgctt gtactgggtc tctcttgctg gaccagatta gagcctggga gctctctggc 60tagcagggaa cccactgctt aagcctcaat aaagcttgcc ttgagtgcta aagtggtgtg 120tgcccatcca ttcggtaact ctggtaccta gagatccctc agaccatcta gactgagtga 180aaaatctcta gcagtggcgc ccgaacaggg acttgaaaac gaaagtagaa ccggaggctg 240aatctctcga cgcaggactc ggctcgttgg tgcacacagc gagaggcgag gcggcggaag 300tgtgagtacg caattttgac tggcggtggc cagaaagtag gagagaggat gggtgcgaga 360gcgtcagtgt taacaggggg aaaattagat caatgggaat caatttattt gagaccaggg 420ggaaagaaaa aatacagaat gaaacattta gtatgggcaa gcagggagct ggaaagattc 480gcttgtaacc caggtctcat ggacacagcg gacggctgtg ccaagttact aaatcaatta 540gaaccagctc tcaagacagg gtcagaagaa ctgcgctctt tatataacgc tctagcagtt 600ctttattgtg tccatagtag gatacagata cacaacacac aggaagcttt ggacaagata 660aaagagaaac aggaacagca caagcccgag ccaaaaaacc cagaagcagg ggcagcggca 720gcaactgata gcaatatcag taggaattat cctctagtcc agactgctca aggacaaatg 780gtacatcagc cgctgacacc cagaacctta aatgcttggg tgaaagtgat agaggagaag 840gcctttagtc cagaagtaat accaatgttt atggccttgt cagaaggggc aacgccctca 900gatctaaata ctatgttaaa tacagtaggg ggacatcagg cagcaatgca gatgctgaag 960gaagtcatca atgaggaagc agcagactgg gataggacac atccagtccc tgtgggacca 1020ctacccccag ggcaactgag agaccctaga ggaagtgata tagcaggaac aactagcacc 1080ctggcagaac aggtggcttg gatgactgct aatcctcctg ttccagtagg agatatttat 1140agaagatgga tagtcctggg gttaaacaga attgtgagaa tgtatagtcc tgtcagcatt 1200ctagagatca aacaaggacc aaaagaaccc ttcagagact atgtagacag gttctacaaa 1260actctaagag cagagcaggc aacacaggaa gtaaagaatt ggatgacaga aacactctta 1320gtacaaaatg caaacccaga ttgtaaacag ctcctaaaag cattagggcc aggagctacc 1380ttagaagaga tgatgacggc ctgccaggga gtggggggac cagcacataa ggcaagagtg 1440ctagcagagg ctatgtcaca ggtgcagcag ccaacaacta gtgtctttgc acaaagggga 1500aactttaaag gcataaggaa acccattaaa tgtttcaatt gtggcaaaga gggccatttg 1560gcaagaaact gtaaggcccc tagaagagga ggctgttgga agtgtgggca agaaggacat 1620caaatgaaag attgtaaaaa tgaaggaaga caggctaatt ttttagggaa gagctggtct 1680cccttcaaag ggagaccagg aaacttcccc cagacaacaa caaggaaaga gcccacagcc 1740ccgccactag agagttatgg gtttcaggag gagaagagca cacaggggaa ggagatgcag 1800gagaaccagg agaggacaga gaactctctg tacccacctt taacttccct cagatcactc 1860tttggcaacg acccgtcatc acagtaaaaa tagggaaaga agtaagagaa gctcttttag 1920atacaggagc tgatgataca gtaatagaag agctacaatt agagggaaaa tggaaaccaa 1980aaatgatagg aggaattgga ggatttatca aagtgagaca atatgataat ataacagtag 2040acatacaggg aagaaaagca gttggtacag tattagtagg accaacacct gttaatatta 2100taggaagaaa tcttttaacc cagattggct gtactttaaa ttttccaata agtcctattg 2160aaactgtacc agtaaaatta aaaccaggaa tggatggccc aaaggtaaaa caatggcctt 2220tgacaacaga aaaaatagag gcattaagag aaatttgtac agaaatggaa aaggaaggaa 2280aaatttctag aatagggcct gagaatccat ataacactcc aatttttgct ataaaaaaga 2340aagatagcac taaatggaga aaattagtag atttcaggga attaaataaa aggacccaag 2400atttttggga agtgcagcta ggaattccac atccagcagg attaaagcag aaaaaatcag 2460tgacagtttt ggatgtagga gatgcttatt tttcatgtcc cttggacaaa gattttagaa 2520agtatacagc ttttaccata cctagtataa acaatgagac acctggtatt agataccagt 2580ataatgtgct gccacaaggc tggaaagggt caccagcaat ttttcagagt acaatgacaa 2640aaattctaga accattcaga gagaaacatc cagagataat catttaccag tacatggatg 2700acctctatgt gggatctgac ttagaactag cacaacatag agaggcagta gaagacctta 2760gagatcatct tttgaagtgg ggctttacga cccctgacaa aaaacatcag aaggaacccc 2820cgttcctctg gatgggatat gaactccatc cagacaaatg gacagtccag ccaataaagt 2880taccagaaaa ggatgtatgg actgtcaatg atatacagaa attagtagga aagttaaatt 2940gggcaagtca gatctatcca ggaatcagag taaaacagct ctgtaaatta atcagaggaa 3000ccaaagcttt gacagaagta gtcaacttta cagaagaagc agaattagaa ctagcagaaa 3060acagggagat attaaaagaa cccctgcatg gagtctatta tgacccagga aaagaattag 3120tagcagaaat tcaaaagcaa ggacaaggtc agtggacata tcagatttat caggagttac 3180ataaaaattt aaaaacagga aagtatgcaa aaatgagatc tgcccatact aatgatataa 3240aacagttagt tgaagtggta aggaaagtgg caacagaaag tatagtaatt tggggaaaga 3300ctcctaaatt tagattacca gtacaaaagg aagtgtggga ggcatggtgg accgatcatt 3360ggcaagcaac ttggattcct gagtgggaat ttgtcaacac tcctcccctt gtaaaattat 3420ggtatcagtt agaaacagag ccaatcagtg gggcagaaac tttctatgta gatggagcag 3480ctaataggga aacaaaattg ggaaaagcag gttttgtgac agatagggga agacagaaag 3540tggtctctat tgcagacacc accaatcaaa aggctgagtt acaagctatc cttatggcct 3600tacaagagtc aggacgggat gtaaacatag tcactgactc tcagtatgct atgggaataa 3660ttcattcaca gccagataaa agtgaatcag aattggtgag ccaaataata gaagagctca 3720taaaaaagga aagagtttat ctctcttggg tacctgcaca taaaggtatt ggaggaaatg 3780agcaggtaga caaattagtt agctcaggaa ttagaaaaat attattccta gatggtatag 3840aaaaagccca agaagatcat gacagatatc acagcaattg gaaagcaatg gccagtgatt 3900ttaacttacc ccccatagtg gcaaaagaaa tagtagccag ctgtgacaaa tgccagctaa 3960aaggggaagc catgcatgga caggtcaatt gtagtccagg agtgtggcaa ttagattgta 4020cacacttaga gggaaaaatc atccttgtgg cggtccatgt ggccagtggc tacttagaag 4080cagaagttat tcctgcagag acaggacagg aaacagcata ttttatttta aagttagctg 4140gaagatggcc agtaaaagtt atacacactg ataatggatc caatttcact agtgccactg 4200taaaagcagc ctgttggtgg gcaaatatca aacaggaatt tgggataccc tacaatcctc 4260aaagtcaggg agcagtagag tccatgaata aagaattaaa gaaaattata ggacaaatca 4320gagatcaagc agaacatcta aagacagcag tgcaaatggc ggttttcatt cacaatttta 4380aaagaaaagg ggggattggg gggtacactg caggggaaag aataatagac ataatagcaa 4440cagacataca gacaacaaat ttacaaacac aaattttaaa agttcaaaat tttcgggttt 4500attacagaga cagcagagat cccatttgga aaggaccagc caaacttctg tggaaaggag 4560aaggggcagt ggtaattcaa gataacgggg atataaaagt agtcccacgt aggaaagcaa 4620aaataattag ggattatgga aaacagatgg caggtgatgg ttgtgtggca agtggacagg 4680atgaaaatca ggaaatggaa tagcttagta aaacatcata tgtatgtgtc aaaaaaggca 4740aaaggatggt attatagaca tcattatgaa acacatcacc caaaaataag ttcagaagta 4800catatcccag taggtcaggc aagattagtg acagtcactt attgggggct aacaacagga 4860gaacagtctt ggcatctagg acatggagta tccatagaat ggagactaag aaaatacaag 4920acacaagttg atcctgaaat ggcagacaag ctaatacatc ttcattattt tgattgtttt 4980acagcctctg ccataaggca agcggtctta gggagaccag tattacctag gtgtgaatat 5040ccagcagggc acaaacaggt aggcacccta caatatctag cactaacagc ctgggtggga 5100gcaaagaaga gaaagccacc cttacctagt gtgactaagc taacagaaga tagatggaac 5160gagcaccaga agatgcaggg ccacagaggg aaccctataa tgaatgggca ctagaattat 5220tagaagaatt aaaaaatgaa gctgtgcgcc attttccaag gatttggcta catgggttag 5280gacaacacat ctataacaca tatggagaca cctgggaggg ggtagaggca attatcagga 5340tactacaaca attactgttt atccattata ggattggctg ccagcacagc agaataggga 5400tcactcctca aaggagaagg aatggaacca gtagatccta gattagagcc ctggaatcat 5460ccaggaagcc aacctaaaac agcttgcaat aattgctatt gtaaaagatg ttgctatcac 5520tgcttatatt gcttcacaaa gaaaggctta ggcatctcat atggcaggaa gaagcggagt 5580caacgacgaa gaactcctca gagcagtaag agtcatcaag atcttatacc agagcagtaa 5640gtaaaacctg tatatatgct gtcattggga ttcatagcgt taggagcagc agttagcata 5700gcagtaatag tctgggcatt actatataga gaatataaga aaataaaatt gcaggaaaaa 5760ataaaacaca taagacagag aataagagaa agagaagaag atagtggcaa tgaaagtgat 5820ggggatgcag agtggttgga tggggatgaa gagtggttgg ttactcttct atcttctagt 5880aagcttgatc aaggtaattg ggtctgaaca acattgggta acagtgtact atggggtacc 5940agtatggaga gaagcagaga caactctttt ctgtgcttca gatgctaaag cccatagtac 6000agaggctcac aacatctggg ccacacaagc atgtgttcct actgatccca atccacaaga 6060agtgctatta cccaatgtaa ctgaaaaatt taatatgtgg gaaaataaaa tggcagacca 6120aatgcaagag gatattatca gtctgtggga acagagctta aagccctgtg ttaaattaac 6180cccattatgt gtaactatgc tttgtaacga tagctatggg gaggaaagga acaatacaaa 6240tatgacaaca agagaaccag acataggata caaacaaatg aaaaattgct cattcaatgc 6300aaccactgag ctaacagata aaaagaagca agtttactct ctgttttatg tagaagatgt 6360agtaccaatc aatgcctata ataaaacata taggctaata aattgtaata ccacagctgt 6420gacacaagct tgtcctaaga cttcctttga gccaattcca atacattact gtgcaccacc 6480aggctttgcc attatgaaat gtaatgaagg aaactttagt ggaaatggaa gctgtacaaa 6540tgtgagtact gtacaatgca cacatggaat aaagccagtg atatccactc agttaatcct 6600aaatggaagc ttaaatacag atggaattgt tattagaaat gatagtcaca gtaatctgtt 6660ggtgcaatgg aatgagacag tgccaataaa ttgtacaagg ccaggaaata atacaggagg 6720acaggtgcag ataggacctg ctatgacatt ttataacata gaaaaaatag taggagacat 6780tagacaagca tactgtaatg tctctaaaga actatgggaa ccaatgtgga atagaacaag 6840agaggaaata aagaaaatcc tggggaaaaa caacataacc ttcagggctc gagagaggaa 6900tgaaggagac ctagaagtga cacacttaat gttcaattgt agaggagagt ttttctattg 6960taacacttcc aaattattta atgaggaatt acttaacgag acaggtgagc ctattactct 7020gccttgtaga ataagacaga ttgtaaattt gtggacaagg gtaggaaaag gaatttatgc 7080accaccaatt cggggagttc ttaactgtac ctccaatatt actggactgg ttctagaata 7140tagtggtggg cctgacacca aggaaacaat agtatatccc tcaggaggaa acatggttaa 7200tctctggaga caagagttgt ataagtacaa agtagttagc atagaaccca taggagtagc 7260accaggtaaa gctaaaagac gcacagtgag tagagaaaaa agagcagcct ttggactagg 7320tgcgctgttt cttgggtttc ttggagcagc agggagcact atgggcgcag cgtcaataac 7380gctgacggta caggcccgga cattattatc tgggatagtg caacagcaga atattctgtt 7440gagagcaata gaggcgcaac aacatttgtt gcaactctca atctggggca ttaaacagct 7500ccaggcaaaa gtccttgcta tagaaagata ccttagggat cagcaaatcc taagtctatg 7560gggctgctca ggaaaaacaa tatgctatac cactgtgcct tggaatgaga cttggagcaa 7620caatacctct tatgatacaa tctggaataa tttaacctgg caacaatggg atgagaaagt 7680aagaaactat tcaggtgtca tttttggact tatagaacag gcacaagaac aacagaacac 7740aaatgagaaa tcactcttgg aattggatca atgggacagt ctgtggagct ggtttggtat 7800tacaaaatgg ctgtggtata taaaaatagc tataatgata gtagcaggca ttgtaggcat 7860aagaatcata agtatagtaa taactataat agcaagagtt aggcagggat attctcccct 7920ttcgttgcag acccttatcc caacagcaag gggaccagac aggccagaag aaacagaagg 7980aggcgttgga gagcaagaca gaggcagatc cgtgcgatta gtgagcggat tctcagctct 8040tgtctgggag gacctccgga acctgttgat cttcctctac caccgcttga cagactcact 8100cttgatactg aggaggactc tggaactcct gggacagagt ctcagcaggg gactgcaact 8160actgaatgaa ctcagaacac acttgtgggg aatacttgca tattggggaa aagagttaag 8220ggatagtgct atcagcttgc ttaatacaac agctattgta gtagcagaag gaacagatag 8280gattatagaa ttagcacaaa gaataggaag gggaatatta cacataccta gaagaatcag 8340acaaggccta gaaagagcac tgatataaga tgggaaagat ttggtcaaag agcagcctag 8400taggatggcc agaaatcaga gaaagaatga gaagacaaac gcaagaacca gcagtagagc 8460cagcagtagg agcaggagca gcttctcaag atctagctaa tcgaggggcc atcaccataa 8520gaaatactag agacaataat gaaagtatag cttggctaga agcacaagaa gaagaagagg 8580aagtaggctt tccagtacgc cctcaggtac cattaaggcc aataacctat aaacaggctt 8640ttgatctttc cttcttttta aaagataagg ggggactgga agggctagtt tggtccagaa 8700aaaggcaaga tattctagac ctctggatgt atcacacaca aggcatcctc cctgactggc 8760ataactacac accagggcca ggaattagat accccgtaac ctttggatgg tgcttcaaac 8820tagtaccatt gtcagctgaa gaagtagaag aggctaatga aggagacaac aatgccctct 8880tacaccccat atgtcaacat ggagcagatg atgatcataa agaagtgttg gtgtggcgat 8940ttgacagctc cctagcaaga agacatgtag caagagagct gcatccggag ttttacaaga 9000actgctgaca agggacttta ctgctgacaa gggactttat acttggggac tttccgccag 9060ggactttcca gggaggtgtg gttgggggag tggcttgccc tcagagctgc ataaaagcag 9120ccgcttctcg cttgtactgg gtctctcttg ctggaccaga ttagagtctg ggagcatatt 9180ggg 9183 2 813 DNA Human immunodeficiency virus type 1 2ttggaagggc tagtttggtc cagaaaaagg caagatattc tagacctctg gatgtatcac 60acacaaggca tcctccctga ctggcataac tacacaccag ggccaggaat tagatacccc 120gtaacctttg gatggtgctt caaactagta ccattgtcag ctgaagaagt agaagaggct 180aatgaaggag acaacaatgc cctcttacac cccatatgtc aacatggagc agatgatgat 240cataaagaag tgttggtgtg gcgatttgac agctccctag caagaagaca tgtagcaaga 300gagctgcatc cggagtttta caagaactgc tgacaaggga ctttactgct gacaagggac 360tttatacttg gggactttcc gccagggact ttccagggag gtgtggttgg gggagtggct 420tgccctcaga gctgcataaa agcagccgct tctcgcttgt actgggtctc tcttgctgga 480ctatacagat tagagcctgg gagctctctg gctagcaggg aacccactgc ttaagcctca 540ataaatacag cttgccttga gtgctaaagt ggtgtgtgcc catccattcg gtaactctgg 600tacctagaga atccctcaga ccatctagac tgagtgaaaa atctctagca gtggcgcccg 660aacagggact tagttgaaaa cgaaagtaga accggaggct gaatctctcg acgcaggact 720cggctcgttg gtgcacacag cgagaggcga ggcggcggaa gtgtgagtac gcaattttga 780ctggcggtgg ccagaaagta ggagagaggg agg 813 3 1539 DNA Human immunodeficiency virus type 1 CDS (1) (1536) 3atg ggt gcg aga gcg tca gtg tta aca ggg gga aaa tta gat caa tgg 48Met Gly Ala Arg Ala Ser Val Leu Thr Gly Gly Lys Leu Asp Gln Trp 1 5 10 15gaa tca att tat ttg aga cca ggg gga aag aaa aaa tac aga atg aaa 96Glu Ser Ile Tyr Leu Arg Pro Gly Gly Lys Lys Lys Tyr Arg Met Lys 20 25 30cat tta gta tgg gca agc agg gag ctg gaa aga ttc gct tgt aac cca 144His Leu Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Cys Asn Pro 35 40 45ggt ctc atg gac aca gcg gac ggc tgt gcc aag tta cta aat caa tta 192Gly Leu Met Asp Thr Ala Asp Gly Cys Ala Lys Leu Leu Asn Gln Leu 50 55 60gaa cca gct ctc aag aca ggg tca gaa gaa ctg cgc tct tta tat aac 240Glu Pro Ala Leu Lys Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn 65 70 75 80gct cta gca gtt ctt tat tgt gtc cat agt agg ata cag ata cac aac 288Ala Leu Ala Val Leu Tyr Cys Val His Ser Arg Ile Gln Ile His Asn 85 90 95aca cag gaa gct ttg gac aag ata aaa gag aaa cag gaa cag cac aag 336Thr Gln Glu Ala Leu Asp Lys Ile Lys Glu Lys Gln Glu Gln His Lys 100 105 110ccc gag cca aaa aac cca gaa gca ggg gca gcg gca gca act gat agc 384Pro Glu Pro Lys Asn Pro Glu Ala Gly Ala Ala Ala Ala Thr Asp Ser 115 120 125aat atc agt agg aat tat cct cta gtc cag act gct caa gga caa atg 432Asn Ile Ser Arg Asn Tyr Pro Leu Val Gln Thr Ala Gln Gly Gln Met 130 135 140gta cat cag ccg ctg aca ccc aga acc tta aat gct tgg gtg aaa gtg 480Val His Gln Pro Leu Thr Pro Arg Thr Leu Asn Ala Trp Val Lys Val145 150 155 160ata gag gag aag gcc ttt agt cca gaa gta ata cca atg ttt atg gcc 528Ile Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Met Ala 165 170 175ttg tca gaa ggg gca acg ccc tca gat cta aat act atg tta aat aca 576Leu Ser Glu Gly Ala Thr Pro Ser Asp Leu Asn Thr Met Leu Asn Thr 180 185 190gta ggg gga cat cag gca gca atg cag atg ctg aag gaa gtc atc aat 624Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Val Ile Asn 195 200 205gag gaa gca gca gac tgg gat agg aca cat cca gtc cct gtg gga cca 672Glu Glu Ala Ala Asp Trp Asp Arg Thr His Pro Val Pro Val Gly Pro 210 215 220cta ccc cca ggg caa ctg aga gac cct aga gga agt gat ata gca gga 720Leu Pro Pro Gly Gln Leu Arg Asp Pro Arg Gly Ser Asp Ile Ala Gly225 230 235 240aca act agc acc ctg gca gaa cag gtg gct tgg atg act gct aat cct 768Thr Thr Ser Thr Leu Ala Glu Gln Val Ala Trp Met Thr Ala Asn Pro 245 250 255cct gtt cca gta gga gat att tat aga aga tgg ata gtc ctg ggg tta 816Pro Val Pro Val Gly Asp Ile Tyr Arg Arg Trp Ile Val Leu Gly Leu 260 265 270aac aga att gtg aga atg tat agt cct gtc agc att cta gag atc aaa 864Asn Arg Ile Val Arg Met Tyr Ser Pro Val Ser Ile Leu Glu Ile Lys 275 280 285caa gga cca aaa gaa ccc ttc aga gac tat gta gac agg ttc tac aaa 912Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys 290 295 300act cta aga gca gag cag gca aca cag gaa gta aag aat tgg atg aca 960Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr305 310 315 320gaa aca ctc tta gta caa aat gca aac cca gat tgt aaa cag ctc cta 1008Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Gln Leu Leu 325 330 335aaa gca tta ggg cca gga gct acc tta gaa gag atg atg acg gcc tgc 1056Lys Ala Leu Gly Pro Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys 340 345 350cag gga gtg ggg gga cca gca cat aag gca aga gtg cta gca gag gct 1104Gln Gly Val Gly Gly Pro Ala His Lys Ala Arg Val Leu Ala Glu Ala 355 360 365atg tca cag gtg cag cag cca aca act agt gtc ttt gca caa agg gga 1152Met Ser Gln Val Gln Gln Pro Thr Thr Ser Val Phe Ala Gln Arg Gly 370 375 380aac ttt aaa ggc ata agg aaa ccc att aaa tgt ttc aat tgt ggc aaa 1200Asn Phe Lys Gly Ile Arg Lys Pro Ile Lys Cys Phe Asn Cys Gly Lys385 390 395 400gag ggc cat ttg gca aga aac tgt aag gcc cct aga aga gga ggc tgt 1248Glu Gly His Leu Ala Arg Asn Cys Lys Ala Pro Arg Arg Gly Gly Cys 405 410 415tgg aag tgt ggg caa gaa gga cat caa atg aaa gat tgt aaa aat gaa 1296Trp Lys Cys Gly Gln Glu Gly His Gln Met Lys Asp Cys Lys Asn Glu 420 425 430gga aga cag gct aat ttt tta ggg aag agc tgg tct ccc ttc aaa ggg 1344Gly Arg Gln Ala Asn Phe Leu Gly Lys Ser Trp Ser Pro Phe Lys Gly 435 440 445aga cca gga aac ttc ccc cag aca aca aca agg aaa gag ccc aca gcc 1392Arg Pro Gly Asn Phe Pro Gln Thr Thr Thr Arg Lys Glu Pro Thr Ala 450 455 460ccg cca cta gag agt tat ggg ttt cag gag gag aag agc aca cag ggg 1440Pro Pro Leu Glu Ser Tyr Gly Phe Gln Glu Glu Lys Ser Thr Gln Gly465 470 475 480aag gag atg cag gag aac cag gag agg aca gag aac tct ctg tac cca 1488Lys Glu Met Gln Glu Asn Gln Glu Arg Thr Glu Asn Ser Leu Tyr Pro 485 490 495cct tta act tcc ctc aga tca ctc ttt ggc aac gac ccg tca tca cag 1536Pro Leu Thr Ser Leu Arg Ser Leu Phe Gly Asn Asp Pro Ser Ser Gln 500 505 510taa 1539 4 512 PRT Human immunodeficiency virus type 1 4Met Gly Ala Arg Ala Ser Val Leu Thr Gly Gly Lys Leu Asp Gln Trp 1 5 10 15Glu Ser Ile Tyr Leu Arg Pro Gly Gly Lys Lys Lys Tyr Arg Met Lys 20 25 30His Leu Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Cys Asn Pro 35 40 45Gly Leu Met Asp Thr Ala Asp Gly Cys Ala Lys Leu Leu Asn Gln Leu 50 55 60Glu Pro Ala Leu Lys Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn 65 70 75 80Ala Leu Ala Val Leu Tyr Cys Val His Ser Arg Ile Gln Ile His Asn 85 90 95Thr Gln Glu Ala Leu Asp Lys Ile Lys Glu Lys Gln Glu Gln His Lys 100 105 110Pro Glu Pro Lys Asn Pro Glu Ala Gly Ala Ala Ala Ala Thr Asp Ser 115 120 125Asn Ile Ser Arg Asn Tyr Pro Leu Val Gln Thr Ala Gln Gly Gln Met 130 135 140Val His Gln Pro Leu Thr Pro Arg Thr Leu Asn Ala Trp Val Lys Val145 150 155 160Ile Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Met Ala 165 170 175Leu Ser Glu Gly Ala Thr Pro Ser Asp Leu Asn Thr Met Leu Asn Thr 180 185 190Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Val Ile Asn 195 200 205Glu Glu Ala Ala Asp Trp Asp Arg Thr His Pro Val Pro Val Gly Pro 210 215 220Leu Pro Pro Gly Gln Leu Arg Asp Pro Arg Gly Ser Asp Ile Ala Gly225 230 235 240Thr Thr Ser Thr Leu Ala Glu Gln Val Ala Trp Met Thr Ala Asn Pro 245 250 255Pro Val Pro Val Gly Asp Ile Tyr Arg Arg Trp Ile Val Leu Gly Leu 260 265 270Asn Arg Ile Val Arg Met Tyr Ser Pro Val Ser Ile Leu Glu Ile Lys 275 280 285Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys 290 295 300Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr305 310 315 320Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Gln Leu Leu 325 330 335Lys Ala Leu Gly Pro Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys 340 345 350Gln Gly Val Gly Gly Pro Ala His Lys Ala Arg Val Leu Ala Glu Ala 355 360 365Met Ser Gln Val Gln Gln Pro Thr Thr Ser Val Phe Ala Gln Arg Gly 370 375 380Asn Phe Lys Gly Ile Arg Lys Pro Ile Lys Cys Phe Asn Cys Gly Lys385 390 395 400Glu Gly His Leu Ala Arg Asn Cys Lys Ala Pro Arg Arg Gly Gly Cys 405 410 415Trp Lys Cys Gly Gln Glu Gly His Gln Met Lys Asp Cys Lys Asn Glu 420 425 430Gly Arg Gln Ala Asn Phe Leu Gly Lys Ser Trp Ser Pro Phe Lys Gly 435 440 445Arg Pro Gly Asn Phe Pro Gln Thr Thr Thr Arg Lys Glu Pro Thr Ala 450 455 460Pro Pro Leu Glu Ser Tyr Gly Phe Gln Glu Glu Lys Ser Thr Gln Gly465 470 475 480Lys Glu Met Gln Glu Asn Gln Glu Arg Thr Glu Asn Ser Leu Tyr Pro 485 490 495Pro Leu Thr Ser Leu Arg Ser Leu Phe Gly Asn Asp Pro Ser Ser Gln 500 505 510 5 3045 DNA Human immunodeficiency virus type 1 CDS (1) (3042) 5ttt ttt agg gaa gag ctg gtc tcc ctt caa agg gag acc agg aaa ctt 48Phe Phe Arg Glu Glu Leu Val Ser Leu Gln Arg Glu Thr Arg Lys Leu 1 5 10 15ccc cca gac aac aac aag gaa aga gcc cac agc ccc gcc act aga gag 96Pro Pro Asp Asn Asn Lys Glu Arg Ala His Ser Pro Ala Thr Arg Glu 20 25 30tta tgg gtt tca gga gga gaa gag cac aca ggg gaa gga gat gca gga 144Leu Trp Val Ser Gly Gly Glu Glu His Thr Gly Glu Gly Asp Ala Gly 35 40 45gaa cca gga gag gac aga gaa ctc tct gta ccc acc ttt aac ttc cct 192Glu Pro Gly Glu Asp Arg Glu Leu Ser Val Pro Thr Phe Asn Phe Pro 50 55 60cag atc act ctt tgg caa cga ccc gtc atc aca gta aaa ata ggg aaa 240Gln Ile Thr Leu Trp Gln Arg Pro Val Ile Thr Val Lys Ile Gly Lys 65 70 75 80gaa gta aga gaa gct ctt tta gat aca gga gct gat gat aca gta ata 288Glu Val Arg Glu Ala Leu Leu Asp Thr Gly Ala Asp Asp Thr Val Ile 85 90 95gaa gag cta caa tta gag gga aaa tgg aaa cca aaa atg ata gga gga 336Glu Glu Leu Gln Leu Glu Gly Lys Trp Lys Pro Lys Met Ile Gly Gly 100 105 110att gga gga ttt atc aaa gtg aga caa tat gat aat ata aca gta gac 384Ile Gly Gly Phe Ile Lys Val Arg Gln Tyr Asp Asn Ile Thr Val Asp 115 120 125ata cag gga aga aaa gca gtt ggt aca gta tta gta gga cca aca cct 432Ile Gln Gly Arg Lys Ala Val Gly Thr Val Leu Val Gly Pro Thr Pro 130 135 140gtt aat att ata gga aga aat ctt tta acc cag att ggc tgt act tta 480Val Asn Ile Ile Gly Arg Asn Leu Leu Thr Gln Ile Gly Cys Thr Leu145 150 155 160aat ttt cca ata agt cct att gaa act gta cca gta aaa tta aaa cca 528Asn Phe Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro 165 170 175gga atg gat ggc cca aag gta aaa caa tgg cct ttg aca aca gaa aaa 576Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Thr Glu Lys 180 185 190ata gag gca tta aga gaa att tgt aca gaa atg gaa aag gaa gga aaa 624Ile Glu Ala Leu Arg Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys 195 200 205att tct aga ata ggg cct gag aat cca tat aac act cca att ttt gct 672Ile Ser Arg Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala 210 215 220ata aaa aag aaa gat agc act aaa tgg aga aaa tta gta gat ttc agg 720Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg225 230 235 240gaa tta aat aaa agg acc caa gat ttt tgg gaa gtg cag cta gga att 768Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile 245 250 255cca cat cca gca gga tta aag cag aaa aaa tca gtg aca gtt ttg gat 816Pro His Pro Ala Gly Leu Lys Gln Lys Lys Ser Val Thr Val Leu Asp 260 265 270gta gga gat gct tat ttt tca tgt ccc ttg gac aaa gat ttt aga aag 864Val Gly Asp Ala Tyr Phe Ser Cys Pro Leu Asp Lys Asp Phe Arg Lys 275 280 285tat aca gct ttt acc ata cct agt ata aac aat gag aca cct ggt att 912Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile 290 295 300aga tac cag tat aat gtg ctg cca caa ggc tgg aaa ggg tca cca gca 960Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala305 310 315 320att ttt cag agt aca atg aca aaa att cta gaa cca ttc aga gag aaa 1008Ile Phe Gln Ser Thr Met Thr Lys Ile Leu Glu Pro Phe Arg Glu Lys 325 330 335cat cca gag ata atc att tac cag tac atg gat gac ctc tat gtg gga 1056His Pro Glu Ile Ile Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly 340 345 350tct gac tta gaa cta gca caa cat aga gag gca gta gaa gac ctc aga 1104Ser Asp Leu Glu Leu Ala Gln His Arg Glu Ala Val Glu Asp Leu Arg 355 360 365gat cat ctt ttg aag tgg ggc ttt acg acc cct gac aaa aaa cat cag 1152Asp His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln 370 375 380aag gag ccc ccg ttc ctc tgg atg gga tat gaa ctc cat cca gac aaa 1200Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys385 390 395 400tgg aca gtc cag cca ata aag tta cca gaa aag gat gta tgg act gtc 1248Trp Thr Val Gln Pro Ile Lys Leu Pro Glu Lys Asp Val Trp Thr Val 405 410 415aat gat ata cag aaa tta gta gga aag tta aat tgg gca agt cag atc 1296Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile 420 425 430tat cca gga atc aga gta aaa cag ctc tgt aaa tta atc aga gga gcc 1344Tyr Pro Gly Ile Arg Val Lys Gln Leu Cys Lys Leu Ile Arg Gly Ala 435 440 445aga gct ttg aca gaa gta gtc aac ttt aca gaa gaa gca gaa tta gaa 1392Arg Ala Leu Thr Glu Val Val Asn Phe Thr Glu Glu Ala Glu Leu Glu 450 455 460cta gca gaa aac agg gag ata tta aaa gaa ccc ctg cat gga gtc tat 1440Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Leu His Gly Val Tyr465 470 475 480tat gac cca gga aaa gaa tta gta gca gaa att caa aag caa gga caa 1488Tyr Asp Pro Gly Lys Glu Leu Val Ala Glu Ile Gln Lys Gln Gly Gln 485 490 495ggt cag tgg aca tat cag att tat cag gag tta cat aaa aat tta aaa 1536Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Leu His Lys Asn Leu Lys 500 505 510aca gga aag tat gca aaa atg aga tct gcc cat act aat gat ata aaa 1584Thr Gly Lys Tyr Ala Lys Met Arg Ser Ala His Thr Asn Asp Ile Lys 515 520 525cag tta gtt gaa gtg gta agg aaa gtg gca aca gaa agt ata gta att 1632Gln Leu Val Glu Val Val Arg Lys Val Ala Thr Glu Ser Ile Val Ile 530 535 540tgg gga aag act cct aaa ttt aga tta cca gta caa aag gaa gtg tgg 1680Trp Gly Lys Thr Pro Lys Phe Arg Leu Pro Val Gln Lys Glu Val Trp545 550 555 560gag gca tgg tgg acc gat cat tgg caa gca act tgg att cct gag tgg 1728Glu Ala Trp Trp Thr Asp His Trp Gln Ala Thr Trp Ile Pro Glu Trp 565 570 575gaa ttt gtc aac act cct ccc ctt gta aaa tta tgg tat cag tta gaa 1776Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu 580 585 590aca gag cca atc agt ggg gca gaa act ttc tat gta gat gga gca gct 1824Thr Glu Pro Ile Ser Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala 595 600 605aat agg gaa aca aaa ttg gga aaa gca ggt ttt gtg aca gat agg gga 1872Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Phe Val Thr Asp Arg Gly 610 615 620aga cag aaa gtg gtc tct att gca gac acc acc aat caa aag gct gag 1920Arg Gln Lys Val Val Ser Ile Ala Asp Thr Thr Asn Gln Lys Ala Glu625 630 635 640tta caa gct atc ctt atg gcc tta caa gag tca gga cgg gat gta aac 1968Leu Gln Ala Ile Leu Met Ala Leu Gln Glu Ser Gly Arg Asp Val Asn 645 650 655ata gtc act gac tct cag tat gct atg gga ata att cat tca cag cca 2016Ile Val Thr Asp Ser Gln Tyr Ala Met Gly Ile Ile His Ser Gln Pro 660 665 670gat aaa agt gaa tca gaa ttg gtg agc caa ata ata gaa gag ctc ata 2064Asp Lys Ser Glu Ser Glu Leu Val Ser Gln Ile Ile Glu Glu Leu Ile 675 680 685aaa aag gaa aga gtt tat ctc tct tgg gta cct gca cat aaa ggt att 2112Lys Lys Glu Arg Val Tyr Leu Ser Trp Val Pro Ala His Lys Gly Ile 690 695 700gga gga aat gag cag gta gac aaa tta gtt agc tca gga att aga aaa 2160Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ser Gly Ile Arg Lys705 710 715 720ata tta ttc cta gat ggt ata gaa aaa gcc caa gaa gat cat gac aga 2208Ile Leu Phe Leu Asp Gly Ile Glu Lys Ala Gln Glu Asp His Asp Arg 725 730 735tat cac agc aat tgg aaa gca atg gcc agt gat ttt aac tta ccc ccc 2256Tyr His Ser Asn Trp Lys Ala Met Ala Ser Asp Phe Asn Leu Pro Pro 740 745 750ata gtg gca aaa gaa ata gta gcc agc tgt gac aaa tgc cag cta aaa 2304Ile Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys 755 760 765ggg gaa gcc atg cat gga cag gtc aat tgt agt cca gga gtg tgg caa 2352Gly Glu Ala Met His Gly Gln Val Asn Cys Ser Pro Gly Val Trp Gln 770 775 780tta gat tgt aca cac tta gag gga aaa atc atc ctt gtg gcg gtc cat 2400Leu Asp Cys Thr His Leu Glu Gly Lys Ile Ile Leu Val Ala Val His785 790 795 800gtg gcc agt ggc tac tta gaa gca gaa gtt att cct gca gag aca gga 2448Val Ala Ser Gly Tyr Leu Glu Ala Glu Val Ile Pro Ala Glu Thr Gly 805 810 815cag gaa aca gca tat ttt att tta aag tta gct gga aga tgg cca gta 2496Gln Glu Thr Ala Tyr Phe Ile Leu Lys Leu Ala Gly Arg Trp Pro Val 820 825 830aaa gtt ata cac act gat aat gga tcc aat ttc act agt gcc act gta 2544Lys Val Ile His Thr Asp Asn Gly Ser Asn Phe Thr Ser Ala Thr Val 835 840 845aaa gca gcc tgt tgg tgg gca aat atc aaa cag gaa ttt ggg ata ccc 2592Lys Ala Ala Cys Trp Trp Ala Asn Ile Lys Gln Glu Phe Gly Ile Pro 850 855 860tac aat cct caa agt cag gga gca gta gag tcc atg aat aaa gaa tta 2640Tyr Asn Pro Gln Ser Gln Gly Ala Val Glu Ser Met Asn Lys Glu Leu865 870 875 880aag aaa att ata gga caa atc aga gat caa gca gaa cat cta aag aca 2688Lys Lys Ile Ile Gly Gln Ile Arg Asp Gln Ala Glu His Leu Lys Thr 885 890 895gca gtg caa atg gcg gtt ttc att cac aat ttt aaa aga aaa ggg ggg 2736Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly 900 905 910att ggg ggg tac act gca ggg gaa aga ata ata gac ata ata gca aca 2784Ile Gly Gly Tyr Thr Ala Gly Glu Arg Ile Ile Asp Ile Ile Ala Thr 915 920 925gac ata cag aca aca aat tta caa aca caa att tta aaa gtt caa aat 2832Asp Ile Gln Thr Thr Asn Leu Gln Thr Gln Ile Leu Lys Val Gln Asn 930 935 940ttt cgg gtt tat tac aga gac agc aga gat ccc att tgg aaa gga cca 2880Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asp Pro Ile Trp Lys Gly Pro945 950 955 960gcc aaa ctt ctg tgg aaa gga gaa ggg gca gtg gta att caa gat aac 2928Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn 965 970 975ggg gat ata aaa gta gtc cca cgt agg aaa gca aaa ata att agg gat 2976Gly Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp 980 985 990tat gga aaa cag atg gca ggt gat ggt tgt gtg gca agt gga cag gat 3024Tyr Gly Lys Gln Met Ala Gly Asp Gly Cys Val Ala Ser Gly Gln Asp 995 1000 1005gaa aat cag gaa atg gaa tag 3045Glu Asn Gln Glu Met Glu 1010 6 1014 PRT Human immunodeficiency virus type 1 6Phe Phe Arg Glu Glu Leu Val Ser Leu Gln Arg Glu Thr Arg Lys Leu 1 5 10 15Pro Pro Asp Asn Asn Lys Glu Arg Ala His Ser Pro Ala Thr Arg Glu 20 25 30Leu Trp Val Ser Gly Gly Glu Glu His Thr Gly Glu Gly Asp Ala Gly 35 40 45Glu Pro Gly Glu Asp Arg Glu Leu Ser Val Pro Thr Phe Asn Phe Pro 50 55 60Gln Ile Thr Leu Trp Gln Arg Pro Val Ile Thr Val Lys Ile Gly Lys 65 70 75 80Glu Val Arg Glu Ala Leu Leu Asp Thr Gly Ala Asp Asp Thr Val Ile 85 90 95Glu Glu Leu Gln Leu Glu Gly Lys Trp Lys Pro Lys Met Ile Gly Gly 100 105 110Ile Gly Gly Phe Ile Lys Val Arg Gln Tyr Asp Asn Ile Thr Val Asp 115 120 125Ile Gln Gly Arg Lys Ala Val Gly Thr Val Leu Val Gly Pro Thr Pro 130 135 140Val Asn Ile Ile Gly Arg Asn Leu Leu Thr Gln Ile Gly Cys Thr Leu145 150 155 160Asn Phe Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro 165 170 175Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Thr Glu Lys 180 185 190Ile Glu Ala Leu Arg Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys 195 200 205Ile Ser Arg Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala 210 215 220Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg225 230 235 240Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile 245 250 255Pro His Pro Ala Gly Leu Lys Gln Lys Lys Ser Val Thr Val Leu Asp 260 265 270Val Gly Asp Ala Tyr Phe Ser Cys Pro Leu Asp Lys Asp Phe Arg Lys 275 280 285Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile 290 295 300Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala305 310 315 320Ile Phe Gln Ser Thr Met Thr Lys Ile Leu Glu Pro Phe Arg Glu Lys 325 330 335His Pro Glu Ile Ile Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly 340 345 350Ser Asp Leu Glu Leu Ala Gln His Arg Glu Ala Val Glu Asp Leu Arg 355 360 365Asp His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln 370 375 380Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys385 390 395 400Trp Thr Val Gln Pro Ile Lys Leu Pro Glu Lys Asp Val Trp Thr Val 405 410 415Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile 420 425 430Tyr Pro Gly Ile Arg Val Lys Gln Leu Cys Lys Leu Ile Arg Gly Ala 435 440 445Arg Ala Leu Thr Glu Val Val Asn Phe Thr Glu Glu Ala Glu Leu Glu 450 455 460Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Leu His Gly Val Tyr465 470 475 480Tyr Asp Pro Gly Lys Glu Leu Val Ala Glu Ile Gln Lys Gln Gly Gln 485 490 495Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Leu His Lys Asn Leu Lys 500 505 510Thr Gly Lys Tyr Ala Lys Met Arg Ser Ala His Thr Asn Asp Ile Lys 515 520 525Gln Leu Val Glu Val Val Arg Lys Val Ala Thr Glu Ser Ile Val Ile 530 535 540Trp Gly Lys Thr Pro Lys Phe Arg Leu Pro Val Gln Lys Glu Val Trp545 550 555 560Glu Ala Trp Trp Thr Asp His Trp Gln Ala Thr Trp Ile Pro Glu Trp 565 570 575Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu 580 585 590Thr Glu Pro Ile Ser Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala 595 600 605Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Phe Val Thr Asp Arg Gly 610 615 620Arg Gln Lys Val Val Ser Ile Ala Asp Thr Thr Asn Gln Lys Ala Glu625 630 635 640Leu Gln Ala Ile Leu Met Ala Leu Gln Glu Ser Gly Arg Asp Val Asn 645 650 655Ile Val Thr Asp Ser Gln Tyr Ala Met Gly Ile Ile His Ser Gln Pro 660 665 670Asp Lys Ser Glu Ser Glu Leu Val Ser Gln Ile Ile Glu Glu Leu Ile 675 680 685Lys Lys Glu Arg Val Tyr Leu Ser Trp Val Pro Ala His Lys Gly Ile 690 695 700Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ser Gly Ile Arg Lys705 710 715 720Ile Leu Phe Leu Asp Gly Ile Glu Lys Ala Gln Glu Asp His Asp Arg 725 730 735Tyr His Ser Asn Trp Lys Ala Met Ala Ser Asp Phe Asn Leu Pro Pro 740 745 750Ile Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys 755 760 765Gly Glu Ala Met His Gly Gln Val Asn Cys Ser Pro Gly Val Trp Gln 770 775 780Leu Asp Cys Thr His Leu Glu Gly Lys Ile Ile Leu Val Ala Val His785 790 795 800Val Ala Ser Gly Tyr Leu Glu Ala Glu Val Ile Pro Ala Glu Thr Gly 805 810 815Gln Glu Thr Ala Tyr Phe Ile Leu Lys Leu Ala Gly Arg Trp Pro Val 820 825 830Lys Val Ile His Thr Asp Asn Gly Ser Asn Phe Thr Ser Ala Thr Val 835 840 845Lys Ala Ala Cys Trp Trp Ala Asn Ile Lys Gln Glu Phe Gly Ile Pro 850 855 860Tyr Asn Pro Gln Ser Gln Gly Ala Val Glu Ser Met Asn Lys Glu Leu865 870 875 880Lys Lys Ile Ile Gly Gln Ile Arg Asp Gln Ala Glu His Leu Lys Thr 885 890 895Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly 900 905 910Ile Gly Gly Tyr Thr Ala Gly Glu Arg Ile Ile Asp Ile Ile Ala Thr 915 920 925Asp Ile Gln Thr Thr Asn Leu Gln Thr Gln Ile Leu Lys Val Gln Asn 930 935 940Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asp Pro Ile Trp Lys Gly Pro945 950 955 960Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn 965 970 975Gly Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp 980 985 990Tyr Gly Lys Gln Met Ala Gly Asp Gly Cys Val Ala Ser Gly Gln Asp 995 1000 1005Glu Asn Gln Glu Met Glu 1010 7 579 DNA Human immunodeficiency virus type 1 CDS (1) (576) 7atg gaa aac aga tgg cag gtg atg gtt gtg tgg caa gtg gac agg atg 48Met Glu Asn Arg Trp Gln Val Met Val Val Trp Gln Val Asp Arg Met 1 5 10 15aaa atc agg aaa tgg aat agc tta gta aaa cat cat atg tat gtg tca 96Lys Ile Arg Lys Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser 20 25 30aaa aag gca aaa gga tgg tat tat aga cat cat tat gaa aca cat cac 144Lys Lys Ala Lys Gly Trp Tyr Tyr Arg His His Tyr Glu Thr His His 35 40 45cca aaa ata agt tca gaa gta cat atc cca gta ggt cag gca aga tta 192Pro Lys Ile Ser Ser Glu Val His Ile Pro Val Gly Gln Ala Arg Leu 50 55 60gtg aca gtc act tat tgg ggg cta aca aca gga gaa cag tct tgg cat 240Val Thr Val Thr Tyr Trp Gly Leu Thr Thr Gly Glu Gln Ser Trp His 65 70 75 80cta gga cat gga gta tcc ata gaa tgg aga cta aga aaa tac aag aca 288Leu Gly His Gly Val Ser Ile Glu Trp Arg Leu Arg Lys Tyr Lys Thr 85 90 95caa gtt gat cct gaa atg gca gac aag cta ata cat ctt cat tat ttt 336Gln Val Asp Pro Glu Met Ala Asp Lys Leu Ile His Leu His Tyr Phe 100 105 110gat tgt ttt aca gcc tct gcc ata agg caa gcg gtc tta ggg aga cca 384Asp Cys Phe Thr Ala Ser Ala Ile Arg Gln Ala Val Leu Gly Arg Pro 115 120 125gta tta cct agg tgt gaa tat cca gca ggg cac aaa cag gta ggc acc 432Val Leu Pro Arg Cys Glu Tyr Pro Ala Gly His Lys Gln Val Gly Thr 130 135 140cta caa tat cta gca cta aca gcc tgg gtg gga gca aag aag aga aag 480Leu Gln Tyr Leu Ala Leu Thr Ala Trp Val Gly Ala Lys Lys Arg Lys145 150 155 160cca ccc tta cct agt gtg act aag cta aca gaa gat aga tgg aac gag 528Pro Pro Leu Pro Ser Val Thr Lys Leu Thr Glu Asp Arg Trp Asn Glu 165 170 175cac cag aag atg cag ggc cac aga ggg aac cct ata atg aat ggg cac 576His Gln Lys Met Gln Gly His Arg Gly Asn Pro Ile Met Asn Gly His 180 185 190tag 579 8 192 PRT Human immunodeficiency virus type 1 8Met Glu Asn Arg Trp Gln Val Met Val Val Trp Gln Val Asp Arg Met 1 5 10 15Lys Ile Arg Lys Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser 20 25 30Lys Lys Ala Lys Gly Trp Tyr Tyr Arg His His Tyr Glu Thr His His 35 40 45Pro Lys Ile Ser Ser Glu Val His Ile Pro Val Gly Gln Ala Arg Leu 50 55 60Val Thr Val Thr Tyr Trp Gly Leu Thr Thr Gly Glu Gln Ser Trp His 65 70 75 80Leu Gly His Gly Val Ser Ile Glu Trp Arg Leu Arg Lys Tyr Lys Thr 85 90 95Gln Val Asp Pro Glu Met Ala Asp Lys Leu Ile His Leu His Tyr Phe 100 105 110Asp Cys Phe Thr Ala Ser Ala Ile Arg Gln Ala Val Leu Gly Arg Pro 115 120 125Val Leu Pro Arg Cys Glu Tyr Pro Ala Gly His Lys Gln Val Gly Thr 130 135 140Leu Gln Tyr Leu Ala Leu Thr Ala Trp Val Gly Ala Lys Lys Arg Lys145 150 155 160Pro Pro Leu Pro Ser Val Thr Lys Leu Thr Glu Asp Arg Trp Asn Glu 165 170 175His Gln Lys Met Gln Gly His Arg Gly Asn Pro Ile Met Asn Gly His 180 185 190 9 288 DNA Human immunodeficiency virus type 1 CDS (1) (285) 9atg gaa cga gca cca gaa gat gca ggg cca cag agg gaa ccc tat aat 48Met Glu Arg Ala Pro Glu Asp Ala Gly Pro Gln Arg Glu Pro Tyr Asn 1 5 10 15gaa tgg gca cta gaa tta tta gaa gaa tta aaa aat gaa gct gtg cgc 96Glu Trp Ala Leu Glu Leu Leu Glu Glu Leu Lys Asn Glu Ala Val Arg 20 25 30cat ttt cca agg att tgg cta cat ggg tta gga caa cac atc tat aac 144His Phe Pro Arg Ile Trp Leu His Gly Leu Gly Gln His Ile Tyr Asn 35 40 45aca tat gga gac acc tgg gag ggg gta gag gca att atc agg ata cta 192Thr Tyr Gly Asp Thr Trp Glu Gly Val Glu Ala Ile Ile Arg Ile Leu 50 55 60caa caa tta ctg ttt atc cat tat agg att ggc tgc cag cac agc aga 240Gln Gln Leu Leu Phe Ile His Tyr Arg Ile Gly Cys Gln His Ser Arg65 70 75 80ata ggg atc act cct caa agg aga agg aat gga acc agt aga tcc 285Ile Gly Ile Thr Pro Gln Arg Arg Arg Asn Gly Thr Ser Arg Ser 85 90 95tag 288 10 95 PRT Human immunodeficiency virus type 1 10Met Glu Arg Ala Pro Glu Asp Ala Gly Pro Gln Arg Glu Pro Tyr Asn 1 5 10 15Glu Trp Ala Leu Glu Leu Leu Glu Glu Leu Lys Asn Glu Ala Val Arg 20 25 30His Phe Pro Arg Ile Trp Leu His Gly Leu Gly Gln His Ile Tyr Asn 35 40 45Thr Tyr Gly Asp Thr Trp Glu Gly Val Glu Ala Ile Ile Arg Ile Leu 50 55 60Gln Gln Leu Leu Phe Ile His Tyr Arg Ile Gly Cys Gln His Ser Arg 65 70 75 80Ile Gly Ile Thr Pro Gln Arg Arg Arg Asn Gly Thr Ser Arg Ser 85 90 95 11 252 DNA Human immunodeficiency virus type 1 CDS (1) (249) 11atg ctg tca ttg gga ttc ata gcg tta gga gca gca gtt agc ata gca 48Met Leu Ser Leu Gly Phe Ile Ala Leu Gly Ala Ala Val Ser Ile Ala 1 5 10 15gta ata gtc tgg gca tta cta tat aga gaa tat aag aaa ata aaa ttg 96Val Ile Val Trp Ala Leu Leu Tyr Arg Glu Tyr Lys Lys Ile Lys Leu 20 25 30cag gaa aaa ata aaa cac ata aga cag aga ata aga gaa aga gaa gaa 144Gln Glu Lys Ile Lys His Ile Arg Gln Arg Ile Arg Glu Arg Glu Glu 35 40 45gat agt ggc aat gaa agt gat ggg gat gca gag tgg ttg gat ggg gat 192Asp Ser Gly Asn Glu Ser Asp Gly Asp Ala Glu Trp Leu Asp Gly Asp 50 55 60gaa gag tgg ttg gtt act ctt cta tct tct agt aag ctt gat caa ggt 240Glu Glu Trp Leu Val Thr Leu Leu Ser Ser Ser Lys Leu Asp Gln Gly65 70 75 80aat tgg gtc tga 252Asn Trp Val 12 83 PRT Human immunodeficiency virus type 1 12Met Leu Ser Leu Gly Phe Ile Ala Leu Gly Ala Ala Val Ser Ile Ala 1 5 10 15Val Ile Val Trp Ala Leu Leu Tyr Arg Glu Tyr Lys Lys Ile Lys Leu 20 25 30Gln Glu Lys Ile Lys His Ile Arg Gln Arg Ile Arg Glu Arg Glu Glu 35 40 45Asp Ser Gly Asn Glu Ser Asp Gly Asp Ala Glu Trp Leu Asp Gly Asp 50 55 60Glu Glu Trp Leu Val Thr Leu Leu Ser Ser Ser Lys Leu Asp Gln Gly 65 70 75 80Asn Trp Val 13 306 DNA Human immunodeficiency virus type 1 CDS (1) (303) 13atg gaa cca gta gat cct aga tta gag ccc tgg aat cat cca gga agc 48Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Asn His Pro Gly Ser 1 5 10 15caa cct aaa aca gct tgc aat aat tgc tat tgt aaa aga tgt tgc tat 96Gln Pro Lys Thr Ala Cys Asn Asn Cys Tyr Cys Lys Arg Cys Cys Tyr 20 25 30cac tgc tta tat tgc ttc aca aag aaa ggc tta ggc atc tca tat ggc 144His Cys Leu Tyr Cys Phe Thr Lys Lys Gly Leu Gly Ile Ser Tyr Gly 35 40 45agg aag aag cgg agt caa cga cga aga act cct cag agc agt aag agt 192Arg Lys Lys Arg Ser Gln Arg Arg Arg Thr Pro Gln Ser Ser Lys Ser 50 55 60cat caa gat ctt ata cca gag cag ccc tta tcc caa cag caa ggg gac 240His Gln Asp Leu Ile Pro Glu Gln Pro Leu Ser Gln Gln Gln Gly Asp 65 70 75 80cag aca ggc cag aag aaa cag aag gag gcg ttg gag agc aag aca gag 288Gln Thr Gly Gln Lys Lys Gln Lys Glu Ala Leu Glu Ser Lys Thr Glu 85 90 95gca gat ccg tgc gat tag 306Ala Asp Pro Cys Asp 100 14 101 PRT Human immunodeficiency virus type 1 14Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Asn His Pro Gly Ser 1 5 10 15Gln Pro Lys Thr Ala Cys Asn Asn Cys Tyr Cys Lys Arg Cys Cys Tyr 20 25 30His Cys Leu Tyr Cys Phe Thr Lys Lys Gly Leu Gly Ile Ser Tyr Gly 35 40 45Arg Lys Lys Arg Ser Gln Arg Arg Arg Thr Pro Gln Ser Ser Lys Ser 50 55 60His Gln Asp Leu Ile Pro Glu Gln Pro Leu Ser Gln Gln Gln Gly Asp 65 70 75 80Gln Thr Gly Gln Lys Lys Gln Lys Glu Ala Leu Glu Ser Lys Thr Glu 85 90 95Ala Asp Pro Cys Asp 100 15 312 DNA Human immunodeficiency virus type 1 CDS (1) (309) 15tg gca gga aga agc gga gtc aac gac gaa gaa ctc ctc aga gca gta 48Met Ala Gly Arg Ser Gly Val Asn Asp Glu Glu Leu Leu Arg Ala Val 1 5 10 15ga gtc atc aag atc tta tac cag agc agt tat ccc aac agc aag ggg 96Arg Val Ile Lys Ile Leu Tyr Gln Ser Ser Tyr Pro Asn Ser Lys Gly 20 25 30cc aga cag gcc aga aga aac aga agg agg cgt tgg aga gca aga cag 144Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg Ala Arg Gln 35 40 45gg cag atc cgt gcg att agt gag cgg att ctc agc tct tgt ctg gga 192Arg Gln Ile Arg Ala Ile Ser Glu Arg Ile Leu Ser Ser Cys Leu Gly 50 55 60ga cct ccg gaa cct gtt gat ctt cct cta cca ccg ctt gac aga ctc 240Gly Pro Pro Glu Pro Val Asp Leu Pro Leu Pro Pro Leu Asp Arg Leu 65 70 75 80ct ctt gat act gag gag gac tct gga act cct ggg aca gag tct cag 288Thr Leu Asp Thr Glu Glu Asp Ser Gly Thr Pro Gly Thr Glu Ser Gln 85 90 95ag ggg act gca act act gaa tga 312Gln Gly Thr Ala Thr Thr Glu 100 16 103 PRT Human immunodeficiency virus type 1 16Met Ala Gly Arg Ser Gly Val Asn Asp Glu Glu Leu Leu Arg Ala Val 1 5 10 15Arg Val Ile Lys Ile Leu Tyr Gln Ser Ser Tyr Pro Asn Ser Lys Gly 20 25 30Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg Ala Arg Gln 35 40 45Arg Gln Ile Arg Ala Ile Ser Glu Arg Ile Leu Ser Ser Cys Leu Gly 50 55 60Gly Pro Pro Glu Pro Val Asp Leu Pro Leu Pro Pro Leu Asp Arg Leu 65 70 75 80Thr Leu Asp Thr Glu Glu Asp Ser Gly Thr Pro Gly Thr Glu Ser Gln 85 90 95Gln Gly Thr Ala Thr Thr Glu 100 17 2559 DNA Human immunodeficiency virus type 1 CDS (1) (2556) 17atg aaa gtg atg ggg atg cag agt ggt tgg atg ggg atg aag agt ggt 48Met Lys Val Met Gly Met Gln Ser Gly Trp Met Gly Met Lys Ser Gly 1 5 10 15tgg tta ctc ttc tat ctt cta gta agc ttg atc aag gta att ggg tct 96Trp Leu Leu Phe Tyr Leu Leu Val Ser Leu Ile Lys Val Ile Gly Ser 20 25 30gaa caa cat tgg gta aca gtg tac tat ggg gta cca gta tgg aga gaa 144Glu Gln His Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Arg Glu 35 40 45gca gag aca act ctt ttc tgt gct tca gat gct aaa gcc cat agt aca 192Ala Glu Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala His Ser Thr 50 55 60gag gct cac aac atc tgg gcc aca caa gca tgt gtt cct act gat ccc 240Glu Ala His Asn Ile Trp Ala Thr Gln Ala Cys Val Pro Thr Asp Pro 65 70 75 80aat cca caa gaa gtg cta tta ccc aat gta act gaa aaa ttt aat atg 288Asn Pro Gln Glu Val Leu Leu Pro Asn Val Thr Glu Lys Phe Asn Met 85 90 95tgg gaa aat aaa atg gca gac caa atg caa gag gat att atc agt ctg 336Trp Glu Asn Lys Met Ala Asp Gln Met Gln Glu Asp Ile Ile Ser Leu 100 105 110tgg gaa cag agc tta aag ccc tgt gtt aaa tta acc cca tta tgt gta 384Trp Glu Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val 115 120 125act atg ctt tgt aac gat agc tat ggg gag gaa agg aac aat aca aat 432Thr Met Leu Cys Asn Asp Ser Tyr Gly Glu Glu Arg Asn Asn Thr Asn 130 135 140atg aca aca aga gaa cca gac ata gga tac aaa caa atg aaa aat tgc 480Met Thr Thr Arg Glu Pro Asp Ile Gly Tyr Lys Gln Met Lys Asn Cys145 150 155 160tca ttc aat gca acc act gag cta aca gat aaa aag aag caa gtt tac 528Ser Phe Asn Ala Thr Thr Glu Leu Thr Asp Lys Lys Lys Gln Val Tyr 165 170 175tct ctg ttt tat gta gaa gat gta gta cca atc aat gcc tat aat aaa 576Ser Leu Phe Tyr Val Glu Asp Val Val Pro Ile Asn Ala Tyr Asn Lys 180 185 190aca tat agg cta ata aat tgt aat acc aca gct gtg aca caa gct tgt 624Thr Tyr Arg Leu Ile Asn Cys Asn Thr Thr Ala Val Thr Gln Ala Cys 195 200 205cct aag act tcc ttt gag cca att cca ata cat tac tgt gca cca cca 672Pro Lys Thr Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala Pro Pro 210 215 220ggc ttt gcc att atg aaa tgt aat gaa gga aac ttt agt gga aat gga 720Gly Phe Ala Ile Met Lys Cys Asn Glu Gly Asn Phe Ser Gly Asn Gly225 230 235 240agc tgt aca aat gtg agt act gta caa tgc aca cat gga ata aag cca 768Ser Cys Thr Asn Val Ser Thr Val Gln Cys Thr His Gly Ile Lys Pro 245 250 255gtg ata tcc act cag tta atc cta aat gga agc tta aat aca gat gga 816Val Ile Ser Thr Gln Leu Ile Leu Asn Gly Ser Leu Asn Thr Asp Gly 260 265 270att gtt att aga aat gat agt cac agt aat ctg ttg gtg caa tgg aat 864Ile Val Ile Arg Asn Asp Ser His Ser Asn Leu Leu Val Gln Trp Asn 275 280 285gag aca gtg cca ata aat tgt aca agg cca gga aat aat aca gga gga 912Glu Thr Val Pro Ile Asn Cys Thr Arg Pro Gly Asn Asn Thr Gly Gly 290 295 300cag gtg cag ata gga cct gct atg aca ttt tat aac ata gaa aaa ata 960Gln Val Gln Ile Gly Pro Ala Met Thr Phe Tyr Asn Ile Glu Lys Ile305 310 315 320gta gga gac att aga caa gca tac tgt aat gtc tct aaa gaa cta tgg 1008Val Gly Asp Ile Arg Gln Ala Tyr Cys Asn Val Ser Lys Glu Leu Trp 325 330 335gaa cca atg tgg aat aga aca aga gag gaa ata aag aaa atc ctg ggg 1056Glu Pro Met Trp Asn Arg Thr Arg Glu Glu Ile Lys Lys Ile Leu Gly 340 345 350aaa aac aac ata acc ttc agg gct cga gag agg aat gaa gga gac cta 1104Lys Asn Asn Ile Thr Phe Arg Ala Arg Glu Arg Asn Glu Gly Asp Leu 355 360 365gaa gtg aca cac tta atg ttc aat tgt aga gga gag ttt ttc tat tgt 1152Glu Val Thr His Leu Met Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys 370 375 380aac act tcc aaa tta ttt aat gag gaa tta ctt aac gag aca ggt gag 1200Asn Thr Ser Lys Leu Phe Asn Glu Glu Leu Leu Asn Glu Thr Gly Glu385 390 395 400cct att act ctg cct tgt aga ata aga cag att gta aat ttg tgg aca 1248Pro Ile Thr Leu Pro Cys Arg Ile Arg Gln Ile Val Asn Leu Trp Thr 405 410 415agg gta gga aaa gga att tat gca cca cca att cgg gga gtt ctt aac 1296Arg Val Gly Lys Gly Ile Tyr Ala Pro Pro Ile Arg Gly Val Leu Asn 420 425 430tgt acc tcc aat att act gga ctg gtt cta gaa tat agt ggt ggg cct 1344Cys Thr Ser Asn Ile Thr Gly Leu Val Leu Glu Tyr Ser Gly Gly Pro 435 440 445gac acc aag gaa aca ata gta tat ccc tca gga gga aac atg gtt aat 1392Asp Thr Lys Glu Thr Ile Val Tyr Pro Ser Gly Gly Asn Met Val Asn 450 455 460ctc tgg aga caa gag ttg tat aag tac aaa gta gtt agc ata gaa ccc 1440Leu Trp Arg Gln Glu Leu Tyr Lys Tyr Lys Val Val Ser Ile Glu Pro465 470 475 480ata gga gta gca cca ggt aaa gct aaa aga cgc aca gtg agt aga gaa 1488Ile Gly Val Ala Pro Gly Lys Ala Lys Arg Arg Thr Val Ser Arg Glu 485 490 495aaa aga gca gcc ttt gga cta ggt gcg ctg ttt ctt ggg ttt ctt gga 1536Lys Arg Ala Ala Phe Gly Leu Gly Ala Leu Phe Leu Gly Phe Leu Gly 500 505 510gca gca ggg agc act atg ggc gca gcg tca ata acg ctg acg gta cag 1584Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln 515 520 525gcc cgg aca tta tta tct ggg ata gtg caa cag cag aat att ctg ttg 1632Ala Arg Thr Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Ile Leu Leu 530 535 540aga gca ata gag gcg caa caa cat ttg ttg caa ctc tca atc tgg ggc 1680Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Ser Ile Trp Gly545 550 555 560att aaa cag ctc cag gca aaa gtc ctt gct ata gaa aga tac ctt agg 1728Ile Lys Gln Leu Gln Ala Lys Val Leu Ala Ile Glu Arg Tyr Leu Arg 565 570 575gat cag caa atc cta agt cta tgg ggc tgc tca gga aaa aca ata tgc 1776Asp Gln Gln Ile Leu Ser Leu Trp Gly Cys Ser Gly Lys Thr Ile Cys 580 585 590tat acc act gtg cct tgg aat gag act tgg agc aac aat acc tct tat 1824Tyr Thr Thr Val Pro Trp Asn Glu Thr Trp Ser Asn Asn Thr Ser Tyr 595 600 605gat aca atc tgg aat aat tta acc tgg caa caa tgg gat gag aaa gta 1872Asp Thr Ile Trp Asn Asn Leu Thr Trp Gln Gln Trp Asp Glu Lys Val 610 615 620aga aac tat tca ggt gtc att ttt gga ctt ata gaa cag gca caa gaa 1920Arg Asn Tyr Ser Gly Val Ile Phe Gly Leu Ile Glu Gln Ala Gln Glu625 630 635 640caa cag aac aca aat gag aaa tca ctc ttg gaa ttg gat caa tgg gac 1968Gln Gln Asn Thr Asn Glu Lys Ser Leu Leu Glu Leu Asp Gln Trp Asp 645 650 655agt ctg tgg agc tgg ttt ggt att aca aaa tgg ctg tgg tat ata aaa 2016Ser Leu Trp Ser Trp Phe Gly Ile Thr Lys Trp Leu Trp Tyr Ile Lys 660 665 670ata gct ata atg ata gta gca ggc att gta ggc ata aga atc ata agt 2064Ile Ala Ile Met Ile Val Ala Gly Ile Val Gly Ile Arg Ile Ile Ser 675 680 685ata gta ata act ata ata gca aga gtt agg cag gga tat tct ccc ctt 2112Ile Val Ile Thr Ile Ile Ala Arg Val Arg Gln Gly Tyr Ser Pro Leu 690 695 700tcg ttg cag acc ctt atc cca aca gca agg gga cca gac agg cca gaa 2160Ser Leu Gln Thr Leu Ile Pro Thr Ala Arg Gly Pro Asp Arg Pro Glu705 710 715 720gaa aca gaa gga ggc gtt gga gag caa gac aga ggc aga tcc gtg cga 2208Glu Thr Glu Gly Gly Val Gly Glu Gln Asp Arg Gly Arg Ser Val Arg 725 730 735tta gtg agc gga ttc tca gct ctt gtc tgg gag gac ctc cgg aac ctg 2256Leu Val Ser Gly Phe Ser Ala Leu Val Trp Glu Asp Leu Arg Asn Leu 740 745 750ttg atc ttc ctc tac cac cgc ttg aca gac tca ctc ttg ata ctg agg 2304Leu Ile Phe Leu Tyr His Arg Leu Thr Asp Ser Leu Leu Ile Leu Arg 755 760 765agg act ctg gaa ctc ctg gga cag agt ctc agc agg gga ctg caa cta 2352Arg Thr Leu Glu Leu Leu Gly Gln Ser Leu Ser Arg Gly Leu Gln Leu 770 775 780ctg aat gaa ctc aga aca cac ttg tgg gga ata ctt gca tat tgg gga 2400Leu Asn Glu Leu Arg Thr His Leu Trp Gly Ile Leu Ala Tyr Trp Gly785 790 795 800aaa gag tta agg gat agt gct atc agc ttg ctt aat aca aca gct att 2448Lys Glu Leu Arg Asp Ser Ala Ile Ser Leu Leu Asn Thr Thr Ala Ile 805 810 815gta gta gca gaa gga aca gat agg att ata gaa tta gca caa aga ata 2496Val Val Ala Glu Gly Thr Asp Arg Ile Ile Glu Leu Ala Gln Arg Ile 820 825 830gga agg gga ata tta cac ata cct aga aga atc aga caa ggc cta gaa 2544Gly Arg Gly Ile Leu His Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu 835 840 845aga gca ctg ata taa 2559Arg Ala Leu Ile 850 18 852 PRT Human immunodeficiency virus type 1 18Met Lys Val Met Gly Met Gln Ser Gly Trp Met Gly Met Lys Ser Gly 1 5 10 15Trp Leu Leu Phe Tyr Leu Leu Val Ser Leu Ile Lys Val Ile Gly Ser 20 25 30Glu Gln His Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Arg Glu 35 40 45Ala Glu Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala His Ser Thr 50 55 60Glu Ala His Asn Ile Trp Ala Thr Gln Ala Cys Val Pro Thr Asp Pro 65 70 75 80Asn Pro Gln Glu Val Leu Leu Pro Asn Val Thr Glu Lys Phe Asn Met 85 90 95Trp Glu Asn Lys Met Ala Asp Gln Met Gln Glu Asp Ile Ile Ser Leu 100 105 110Trp Glu Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val 115 120 125Thr Met Leu Cys Asn Asp Ser Tyr Gly Glu Glu Arg Asn Asn Thr Asn 130 135 140Met Thr Thr Arg Glu Pro Asp Ile Gly Tyr Lys Gln Met Lys Asn Cys145 150 155 160Ser Phe Asn Ala Thr Thr Glu Leu Thr Asp Lys Lys Lys Gln Val Tyr 165 170 175Ser Leu Phe Tyr Val Glu Asp Val Val Pro Ile Asn Ala Tyr Asn Lys 180 185 190Thr Tyr Arg Leu Ile Asn Cys Asn Thr Thr Ala Val Thr Gln Ala Cys 195 200 205Pro Lys Thr Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala Pro Pro 210 215 220Gly Phe Ala Ile Met Lys Cys Asn Glu Gly Asn Phe Ser Gly Asn Gly225 230 235 240Ser Cys Thr Asn Val Ser Thr Val Gln Cys Thr His Gly Ile Lys Pro 245 250 255Val Ile Ser Thr Gln Leu Ile Leu Asn Gly Ser Leu Asn Thr Asp Gly 260 265 270Ile Val Ile Arg Asn Asp Ser His Ser Asn Leu Leu Val Gln Trp Asn 275 280 285Glu Thr Val Pro Ile Asn Cys Thr Arg Pro Gly Asn Asn Thr Gly Gly 290 295 300Gln Val Gln Ile Gly Pro Ala Met Thr Phe Tyr Asn Ile Glu Lys Ile305 310 315 320Val Gly Asp Ile Arg Gln Ala Tyr Cys Asn Val Ser Lys Glu Leu Trp 325 330 335Glu Pro Met Trp Asn Arg Thr Arg Glu Glu Ile Lys Lys Ile Leu Gly 340 345 350Lys Asn Asn Ile Thr Phe Arg Ala Arg Glu Arg Asn Glu Gly Asp Leu 355 360 365Glu Val Thr His Leu Met Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys 370 375 380Asn Thr Ser Lys Leu Phe Asn Glu Glu Leu Leu Asn Glu Thr Gly Glu385 390 395 400Pro Ile Thr Leu Pro Cys Arg Ile Arg Gln Ile Val Asn Leu Trp Thr 405 410 415Arg Val Gly Lys Gly Ile Tyr Ala Pro Pro Ile Arg Gly Val Leu Asn 420 425 430Cys Thr Ser Asn Ile Thr Gly Leu Val Leu Glu Tyr Ser Gly Gly Pro 435 440 445Asp Thr Lys Glu Thr Ile Val Tyr Pro Ser Gly Gly Asn Met Val Asn 450 455 460Leu Trp Arg Gln Glu Leu Tyr Lys Tyr Lys Val Val Ser Ile Glu Pro465 470 475 480Ile Gly Val Ala Pro Gly Lys Ala Lys Arg Arg Thr Val Ser Arg Glu 485 490 495Lys Arg Ala Ala Phe Gly Leu Gly Ala Leu Phe Leu Gly Phe Leu Gly 500 505 510Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln 515 520 525Ala Arg Thr Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Ile Leu Leu 530 535 540Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Ser Ile Trp Gly545 550 555 560Ile Lys Gln Leu Gln Ala Lys Val Leu Ala Ile Glu Arg Tyr Leu Arg 565 570 575Asp Gln Gln Ile Leu Ser Leu Trp Gly Cys Ser Gly Lys Thr Ile Cys 580 585 590Tyr Thr Thr Val Pro Trp Asn Glu Thr Trp Ser Asn Asn Thr Ser Tyr 595 600 605Asp Thr Ile Trp Asn Asn Leu Thr Trp Gln Gln Trp Asp Glu Lys Val 610 615 620Arg Asn Tyr Ser Gly Val Ile Phe Gly Leu Ile Glu Gln Ala Gln Glu625 630 635 640Gln Gln Asn Thr Asn Glu Lys Ser Leu Leu Glu Leu Asp Gln Trp Asp 645 650 655Ser Leu Trp Ser Trp Phe Gly Ile Thr Lys Trp Leu Trp Tyr Ile Lys 660 665 670Ile Ala Ile Met Ile Val Ala Gly Ile Val Gly Ile Arg Ile Ile Ser 675 680 685Ile Val Ile Thr Ile Ile Ala Arg Val Arg Gln Gly Tyr Ser Pro Leu 690 695 700Ser Leu Gln Thr Leu Ile Pro Thr Ala Arg Gly Pro Asp Arg Pro Glu705 710 715 720Glu Thr Glu Gly Gly Val Gly Glu Gln Asp Arg Gly Arg Ser Val Arg 725 730 735Leu Val Ser Gly Phe Ser Ala Leu Val Trp Glu Asp Leu Arg Asn Leu 740 745 750Leu Ile Phe Leu Tyr His Arg Leu Thr Asp Ser Leu Leu Ile Leu Arg 755 760 765Arg Thr Leu Glu Leu Leu Gly Gln Ser Leu Ser Arg Gly Leu Gln Leu 770 775 780Leu Asn Glu Leu Arg Thr His Leu Trp Gly Ile Leu Ala Tyr Trp Gly785 790 795 800Lys Glu Leu Arg Asp Ser Ala Ile Ser Leu Leu Asn Thr Thr Ala Ile 805 810 815Val Val Ala Glu Gly Thr Asp Arg Ile Ile Glu Leu Ala Gln Arg Ile 820 825 830Gly Arg Gly Ile Leu His Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu 835 840 845Arg Ala Leu Ile 850 19 639 DNA Human immunodeficiency virus type 1 CDS (1) (636) 19atg gga aag att tgg tca aag agc agc cta gta gga tgg cca gaa atc 48Met Gly Lys Ile Trp Ser Lys Ser Ser Leu Val Gly Trp Pro Glu Ile 1 5 10 15aga gaa aga atg aga aga caa acg caa gaa cca gca gta gag cca gca 96Arg Glu Arg Met Arg Arg Gln Thr Gln Glu Pro Ala Val Glu Pro Ala 20 25 30gta gga gca gga gca gct tct caa gat cta gct aat cga ggg gcc atc 144Val Gly Ala Gly Ala Ala Ser Gln Asp Leu Ala Asn Arg Gly Ala Ile 35 40 45acc ata aga aat act aga gac aat aat gaa agt ata gct tgg cta gaa 192Thr Ile Arg Asn Thr Arg Asp Asn Asn Glu Ser Ile Ala Trp Leu Glu 50 55 60gca caa gaa gaa gaa gag gaa gta ggc ttt cca gta cgc cct cag gta 240Ala Gln Glu Glu Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val 65 70 75 80cca tta agg cca ata acc tat aaa cag gct ttt gat ctt tcc ttc ttt 288Pro Leu Arg Pro Ile Thr Tyr Lys Gln Ala Phe Asp Leu Ser Phe Phe 85 90 95tta aaa gat aag ggg gga ctg gaa ggg cta gtt tgg tcc aga aaa agg 336Leu Lys Asp Lys Gly Gly Leu Glu Gly Leu Val Trp Ser Arg Lys Arg 100 105 110caa gat att cta gac ctc tgg atg tat cac aca caa ggc atc ctc cct 384Gln Asp Ile Leu Asp Leu Trp Met Tyr His Thr Gln Gly Ile Leu Pro 115 120 125gac tgg cat aac tac aca cca ggg cca gga att aga tac ccc gta acc 432Asp Trp His Asn Tyr Thr Pro Gly Pro Gly Ile Arg Tyr Pro Val Thr 130 135 140ttt gga tgg tgc ttc aaa cta gta cca ttg tca gct gaa gaa gta gaa 480Phe Gly Trp Cys Phe Lys Leu Val Pro Leu Ser Ala Glu Glu Val Glu145 150 155 160gag gct aat gaa gga gac aac aat gcc ctc tta cac ccc ata tgt caa 528Glu Ala Asn Glu Gly Asp Asn Asn Ala Leu Leu His Pro Ile Cys Gln 165 170 175cat gga gca gat gat gat cat aaa gaa gtg ttg gtg tgg cga ttt gac 576His Gly Ala Asp Asp Asp His Lys Glu Val Leu Val Trp Arg Phe Asp 180 185 190agc tcc cta gca aga aga cat gta gca aga gag ctg cat ccg gag ttt 624Ser Ser Leu Ala Arg Arg His Val Ala Arg Glu Leu His Pro Glu Phe 195 200 205tac aag aac tgc tga 639Tyr Lys Asn Cys 210 20 212 PRT Human immunodeficiency virus type 1 20Met Gly Lys Ile Trp Ser Lys Ser Ser Leu Val Gly Trp Pro Glu Ile 1 5 10 15Arg Glu Arg Met Arg Arg Gln Thr Gln Glu Pro Ala Val Glu Pro Ala 20 25 30Val Gly Ala Gly Ala Ala Ser Gln Asp Leu Ala Asn Arg Gly Ala Ile 35 40 45Thr Ile Arg Asn Thr Arg Asp Asn Asn Glu Ser Ile Ala Trp Leu Glu 50 55 60Ala Gln Glu Glu Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val 65 70 75 80Pro Leu Arg Pro Ile Thr Tyr Lys Gln Ala Phe Asp Leu Ser Phe Phe 85 90 95Leu Lys Asp Lys Gly Gly Leu Glu Gly Leu Val Trp Ser Arg Lys Arg 100 105 110Gln Asp Ile Leu Asp Leu Trp Met Tyr His Thr Gln Gly Ile Leu Pro 115 120 125Asp Trp His Asn Tyr Thr Pro Gly Pro Gly Ile Arg Tyr Pro Val Thr 130 135 140Phe Gly Trp Cys Phe Lys Leu Val Pro Leu Ser Ala Glu Glu Val Glu145 150 155 160Glu Ala Asn Glu Gly Asp Asn Asn Ala Leu Leu His Pro Ile Cys Gln 165 170 175His Gly Ala Asp Asp Asp His Lys Glu Val Leu Val Trp Arg Phe Asp 180 185 190Ser Ser Leu Ala Arg Arg His Val Ala Arg Glu Leu His Pro Glu Phe 195 200 205Tyr Lys Asn Cys 210 21 20 DNA artificial sequence primer 21attgcgtact cacacttccg 20 22 17 DNA artificial sequence primer 22ggcaagcagg gagctgg 17 23 18 DNA artificial sequence primer 23tccttgagca gtctggac 18 24 18 DNA artificial sequence primer 24gaacaggagg attagcag 18 25 18 DNA artificial sequence primer 25agcagaggct atgtcaca 18 26 19 DNA artificial sequence primer 26tgtaaggccc ctagaagag 19 27 18 DNA artificial sequence primer 27acagagaact ctctgtac 18 28 18 DNA artificial sequence primer 28aagaaaagca gttggtac 18 29 17 DNA artificial sequence primer 29tttcttccct gtatgtc 17 30 18 DNA artificial sequence primer 30gttatatgga ttctcagg 18 31 19 DNA artificial sequence primer 31tggcagcaca ttatactgg 19 32 23 DNA artificial sequence primer 32atcatttacc agtacatgga cga 23 33 18 DNA artificial sequence primer 33tgtcaggggt cgtaaagc 18 34 18 DNA artificial sequence primer 34tcctctggat gggatatg 18 35 18 DNA artificial sequence primer 35tctatccagg aatcagag 18 36 18 DNA artificial sequence primer 36aatgagatct gcccatac 18 37 18 DNA artificial sequence primer 37tgacagatag gggaagac 18 38 18 DNA artificial sequence primer 38aaccgccatt tgcactgc 18 39 18 DNA artificial sequence primer 39acatggaccg ccacaagg 18 40 18 DNA artificial sequence primer 40agcaacagac atacagac 18 41 18 DNA artificial sequence primer 41aaagtagtcc cacgtagg 18 42 18 DNA artificial sequence primer 42atatcccagt aggtcagg 18 43 18 DNA artificial sequence primer 43tctagcacta acagcctg 18 44 18 DNA artificial sequence primer 44actcttactg ctctgagg 18 45 18 DNA artificial sequence primer 45ccatagtaca ctgttacc 18 46 20 DNA artificial sequence primer 46catagctatc gttacaaagc 20 47 18 DNA artificial sequence primer 47tcataatggc aaagcctg 18 48 18 DNA artificial sequence primer 48ctattccaca ttggttcc 18 49 18 DNA artificial sequence primer 49attctagaac cagtccag 18 50 20 DNA artificial sequence primer for HIV type 1 50ccttagggat cagcaaatcc 20 51 18 DNA artificial sequence primer 51tgggacagtc tgtggagc 18 52 18 DNA artificial sequence primer 52ttctcagctc ttgtctgg 18 53 18 DNA artificial sequence primer 53attaagcaag ctgatagc 18 54 16 DNA artificial sequence primer 54tgtgcttcta gccaag 16 55 18 DNA artificial sequence primer 55gctccatgtt gacatatg 18 56 18 DNA artificial sequence primer 56agagagaccc agtacaag 18 57 20 DNA artificial sequence primer 57ataaaagcag ccgcttctcg 20 58 35 PRT Human immunodeficiency virus type 1 58Cys Thr Arg Pro Gly Asn Asn Thr Gly Gly Gln Val Gln Ile Gly Pro 1 5 10 15Ala Met Thr Phe Tyr Asn Ile Glu Lys Ile Val Gly Asp Ile Arg Gln 20 25 30Ala Tyr Cys 35 59 35 PRT Human immunodeficiency virus type 1 59Cys His Arg Pro Gly Asn Asn Thr Arg Gly Glu Val Gln Ile Gly Pro 1 5 10 15Gly Met Thr Phe Tyr Asn Ile Glu Asn Val Tyr Gly Asp Thr Arg Ser 20 25 30Ala Tyr Cys 35 60 35 PRT Human immunodeficiency virus type 1 60Cys Ile Arg Pro Gly Asn Arg Thr Tyr Arg Asn Leu Gln Ile Gly Pro1 5 10 15Gly Met Thr Phe Tyr Asn Val Glu Ile Ala Thr Gly Asp Ile Arg Lys 20 25 30Ala Phe Cys 35 61 35 PRT Human immunodeficiency virus type 1 61Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Val Arg Ile Gly Pro1 5 10 15Gly Gln Ala Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile Arg Gln 20 25 30Ala His Cys 35 62 (corresponds to 4235.1 pol of Figure 1) 18 DNA artificial sequence primer 62agcaacagac atacagac 18 63 (corresponds to 4235.2 vif of Figure 1) 18 DNA artificial sequence primer 63aaagtagtcc cacgtagg 18 64 (corresponds to 4235.3 tat of Figure 1) 18 DNA artificial sequence primer 64atatcccagt aggtcagg 18 65 (corresponds to 4235.4 tat of Figure 1) 18 DNA artificial sequence primer 65tctagcacta acagcctg 18 66 (corresponds to 4481.1 pol of Figure 1) 18 DNA artificial sequence primer 66aaccgccatt tgcactgc 18 67 (corresponds to 4481.2 pol of Figure 1) 18 DNA artificial sequence primer 67acatggaccg ccacaagg 18 68 (corresponds to Gag 6 gag of Figure 1) 18 DNA artificial sequence primer 68agcagaggct atgtcaca 18 69 (corresponds to GAG Y AS1 gag of Figure 1) 18 DNA artificial sequence primer 69gaacaggagg attagcag 18 70 (GAG Y AS1.1 ltr of Figure 1) 18 DNA artificial sequence primer 70tccttgagca gtctggac 18 71 (corresponds to GAG Y S1.1 gag of Figure 1) 18 DNA Human immunodeficiency virus type 1 71acagagaact ctctgtac 18 72 (corresponds to GAG Y S1.2 gag of Figure 1) 18 DNA artificial sequence primer 72aagaaaagca gttggtac 18 73 (corresponds to GAG Y S1 gag of Figure 1) 19 DNA artificial sequence primer 73tgtaaggccc ctagaagag 19 74 (corresponds to LPBS.1 ltr of Figure 1) 17 DNA artificial sequence primer 74ggcaagcagg gagctgg 17 75 (corresponds to LSi A1 ltr of Figure 1) 18 DNA artificial sequence primer 75agagagaccc agtacaag 18 76 (corresponds to LSI AS1.1 ltr of Figure 1) 18 DNA artificial sequence primer 76gctccatgtt gacatatg 18 77 (corresponds to LSI AS1.2 nef of Figure 1) 16 DNA artificial sequence primer 77tgtgcttcta gccaag 16 78 (corresponds to LSI AS1.3 nef of Figure 1) 18 DNA artificial sequence primer 78attaagcaag ctgatagc 18 79 (corresponds to SK 68.1 env of Figure 1) 20 DNA artificial sequence primer 79ccttagggat cagcaaatcc 20 80 (corresponds to SK 68.2 env of Figure 1) 18 DNA artificial sequence primer 80tgggacagtc tgtggagc 18 81 (corresponds to SK 68.3 env of Figure 1) 18 DNA artificial sequence primer 81ttctcagctc ttgtctgg 18 82 (corresponds to SK 69.1 env of Figure 1) 18 DNA artificial sequence primer 82attctagaac cagtccag 18 83 (corresponds to SK 69.2 env of Figure 1) 18 DNA artificial sequence primer 83ctattccaca ttggttcc 18 84 (corresponds to SK 69.3 env of Figure 1) 18 DNA artificial sequence primer 84tcataatggc aaagcctg 18 85 (corresponds to SK 69.4 env of Figure 1) 20 DNA artificial sequence primer 85catagctatc gttacaaagc 20 86 (corresponds to SK 69.5 env of Figure 1) 18 DNA artificial sequence primer 86ccatagtaca ctgttacc 18 87 (corresponds to SK 69.6 env of Figure 1) 18 DNA artificial sequence primer 87actcttactg ctctgagg 18 88 (corresponds to YLG ltr of Figure 1) 20 DNA artificial sequence primer 88attgcgtact cacacttccg 20 89 (corresponds to YLPA ltr of Figure 1) 20 DNA artificial sequence primer 89ataaaagcag ccgcttctcg 20 90 (corresponds to YRT2-1 pol of Figure 1) 18 DNA artificial sequence primer 90tcctctggat gggatatg 18 91 (corresponds to YRT2-2 pol of Figure 1) 18 DNA artificial sequence primer 91tctatccagg aatcagag 18 92 (corresponds to YRT2-4 pol of Figure 1) 18 DNA artificial sequence primer 92tgacagatag gggaagac 18 93 (corresponds to YRT2 pol of Figure 1) 23 DNA artificial sequence primer 93atcatttacc agtacatgga cga 23 94 (corresponds to YRT3 pol of Figure 1) 18 DNA artificial sequence primer 94aatgagatct gcccatac 18 95 (corresponds to YRT AS1.1 pol of Figure 1) 19 DNA artificial sequence primer 95tggcagcaca ttatactgg 19 96 (corresponds to YRT AS1.2 pol of Figure 1) 18 DNA artificial sequence primer 96gttatatgga ttctcagg 18 97 (corresponds to YRT AS1.3 pol of Figure 1) 17 DNA artificial sequence primer 97tttcttccct gtatgtc 17 98 (corresponds to YRT AS.1 pol of Figure 1) 18 DNA artificial sequence primer 98tgtcaggggt cgtaaagc 18

Claims

1. An isolated peptide comprising SEQ ID NO: 58.

2. A peptide of claim 1, comprising SEQ ID NO: 18.

3. An isolated peptide expressed by the env gene comprising a sequence encoding SEQ ID NO: 58.

4. A peptide of claim 3, wherein the env gene is of a non-M, non-O HIV-1 strain exhibiting morphological and immunological characteristics of the retrovirus designated YBF30 and deposited as CNCM No. 1-1753.

5. A peptide of claim 3, wherein the peptide comprises SEQ ID NO: 18.

6. A peptide of claim 3, wherein the peptide comprises a V3 loop.

7. An isolated peptide consisting of SEQ ID NO: 58.

8. An isolated peptide expressed by the env gene of a non-M, non-O HIV-1 strain comprising SEQ ID NO: 58, wherein the peptide exhibits antibody-recognition capacity and can be recognized by antibodies which are induced by a non-M, non-O HIV-1 virus and which are present in a biological sample obtained following an infection with a non-M, non-O HIV-1 strain.

9. An immunogenic composition comprising an isolated peptide comprising SEQ ID NO: 18 or 58.

10. A kit for detecting a non-M, non-O HIV-1 virus, comprising at least one of the peptides of any one of claims 1 to 8.